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Abstract 
 
Diabetes mellitus is a worldwide health issue. It is a major and growing cause of morbidity 
and mortality. Rates of end-organ damage are increasing proportionately, as are the 
associated personal, societal and economic costs. Diabetic foot ulceration is responsible for 
a significant proportion of this. The development of diabetic foot ulceration is complex 
with multiple injurious processes potentially affecting a foot at any time. Defining the 
significance of ischaemia as a consequence of peripheral arterial occlusive disease can be 
difficult and identifying which patients may benefit from revascularisation in terms of 
reversing of the natural history of the disease process remains poorly understood.  
 
The utility of the University of Texas classification to identify patients at highest risk of 
major adverse clinical events has been explored from 971 ulcer episodes affecting 515 
limbs (388 patients). Peripheral arterial occlusive disease was identified in 44.6%. These 
patients had a significantly higher risk of major amputation than patients without 
peripheral arterial occlusive disease (13.5 versus 4%). University of Texas scoring would 
appear to robustly identify patients at highest risk of major adverse clinical events.  
 
The potential usefulness of Connexin 43 and its phosphorylated isoform Connexin 
43(Serine368) as biological markers of ischaemia in skin have been explored. 
Immunohistochemistry provided qualitative data demonstrating up regulation of Connexin 
43(Serine368) in skin biopsies from ischaemic feet – this is a novel finding. Connexin 43 
(Serine368) was not identified in any of the controls nor in proximal skin biopsies of 
patients with peripheral arterial occlusive disease. Connexin 43 expression did not appear 
to be modified. 
 
When human fibroblasts and keratinocytes were subjected to hypoxic conditions (1% 
oxygen/4% carbon dioxide/nitrogen) in vitro, both Connexin 43 and Connexin 
43(Serine368) were up regulated with protein expression peaking between 12 to 24 and 6 
to 12 hours respectively. Peptidoglycan challenge appeared to up-regulate the expression 
of Connexin 43 protein, but did not influence the expression of Connexin 43(Serine368). 
These data suggest that Connexin 43(Serine 368) may have potential utility as a biological 
marker of ischaemia in human skin  
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Glossary of Terms 
 
Ankle Brachial Pressure Index (ABPI) - A ratio of the systolic blood pressure recorded in a 
tibial artery at the level of the ankle and the brachial artery in the arm 
Bradford protein assay - a spectroscopic analytical procedure used to determine the protein 
concentration 
Connexin (Cx) – Structurally related transmembrane proteins which form gap junctions 
Cryostat - A cold chamber in which frozen tissue is divided with a microtome 
Critical Limb Ischaemia (CLI) – A clinical condition associated with peripheral arterial 
occlusive disease in which there is threat to the long-term viability of the limb without 
intervention  
Diabetes Mellitus (DM) – A metabolic condition associated with the development of 
hyperglycaemia as a consequence of a failure of insulin production or the development of 
insulin resistance 
Fibroblast – A cell type that is involved in the synthesis of extra-cellular matrix and 
collagen. Fibroblasts have an important role in wound healing 
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Chapter 1 - Definition of critical limb ischaemia and a review of the challenges of 
diabetic foot ulceration, with discussion of the potential utility of Connexin 43 as a 
biological marker of ischaemia in patients with atherosclerotic arterial disease of the 
lower limb    
 
1.1 Introduction 
 
Peripheral arterial occlusive disease (PAOD) of the lower limb is a consequence of 
systemic atherosclerosis. The Edinburgh Artery Study reported a prevalence of 8% for 
asymptomatic PAOD in a study population of 1,592 participants (aged 55–74 years), with 
symptomatic disease (intermittent claudication) diagnosed in 4.6% [Fowkes 1991]. In the 
symptomatic population group as many as 20% of patients may have a diagnosis of 
diabetes mellitus (DM) [Murabito 1997]. 
 
A small number of patients with severely symptomatic PAOD will develop critical limb 
ischaemia (CLI) with threat to limb viability. The estimated incidence of CLI in Europe 
and North America is 500-1,000 per million of the population. At 1 year, approximately 
25% of these patients will have died and as many as one-third will have had a major limb 
amputation performed [Norgren 2007]. There are clear criteria for the diagnosis of CLI 
[European Working Group on Critical Limb Ischaemia 1992] which include either: More 
than 2-weeks of recurrent foot pain requiring the regular use of analgesics, associated with 
an absolute ankle systolic blood pressure of 50mmHg or less (or an absolute systolic toe 
pressure of 30mmHg or less) or; A non-healing wound or gangrene of the toes or foot, with 
similar haemodynamic measurements. 
 
Diagnosing CLI in patients with DM and foot ulceration can be difficult and confusing. 
Frequently a distal pattern of arterial disease (infra-geniculate) is encountered [Rueda 
2008]. In the context of neuropathy pain may be absent. These features can be 
compounded by the presence of arteriovenous shunting conferring a red, hyperaemic 
colour to the foot. 
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1.2 Diabetic foot ulceration: A significant and complex problem 
 
DM is a worldwide health issue, it has been estimated that 422 million adults were living 
with the disease in 2014. It is a major and growing cause of morbidity and mortality [WHO 
2016]. In Scotland the prevalence of type II DM is rising; over the next 25 years one in ten 
people is expected to develop the disease [Scottish Executive 2006]. 
 
Rates of end-organ damage are increasing proportionately, as are the associated personal, 
societal and economic costs. The National Health Service currently spends approximately 
10% of the healthcare budget (approximately £9 billion per year) on the management of 
DM and its complications. Diabetic foot ulceration (DFU) is responsible for a significant 
proportion of this cost. Worldwide it is estimated that 50% of all non-traumatic lower limb 
amputations are performed for patients with a diagnosis of DM [WHO 2016].  
 
There is wide variation in reported rates of (DFU), probably reflecting ethnicity, social 
deprivation and case ascertainment [Jeffcoate 2012]. DFU is a relapsing-remitting process 
that has a high impact on patients, their carers and health care systems [Reiber 1998, 
Boulton 2005].   
 
The natural history of DFU in the developed world has been well described with a 
mortality rate of 16.9% and an amputation (predominantly infra-malleolar) rate of 11% at 
one year [Jeffcoate 2006].  In 25-80% there will be persistence or ulcer recurrence after 
one year of treatment [Lavery 2007].  
 
The development and recurrence of DFU is complex with multiple injurious processes 
potentially affecting a foot at any time. Neuropathy and ischaemia (as a consequence of 
PAOD and/or endothelial dysfunction, often referred to as microvascular disease) are 
fundamental components in the development of ulceration – with the term neuroischaemic 
ulceration describing the clinical state where there is both neuropathy and an ischaemic 
component (Figure 1.1).  
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Figure 1.1 Neuroischaemic diabetic foot ulceration 
This example eloquently demonstrates the challenges associated with DFU – there has 
been minor amputation of the fourth and fifth toes with wound healing (without arterial 
intervention). Subsequent to this there has been amputation of the hallux with wound 
failure despite arterial reconstruction (femoro-distal bypass). The clinical course for this 
patient was further deterioration in the foot resulting in major limb amputation (transtibial), 
with failure to rehabilitate with a prosthetic limb and cardiovascular death within 12-
months. 
 
 
 
Other important pathophysiological processes include repeated episodes of acute and/or 
chronic infection, mechanical changes as a consequence of Charcot change or surgical 
interventions and metabolic dysfunction associated with hyperglycaemia (at a cellular level 
this may result in impaired Nitric Oxide synthesis [Goldin 2006], structural and functional 
changes of the fibroblasts [Loots 1999] and an increase in matrix metalloproteinase 
activity [Vaalamo 1999]) all of which can contribute to tissue damage. These processes 
can result in a progressive cycle of tissue destruction, septic episodes, and mechanical foot 
deformity (there is loss of intrinsic muscle mass and no opposition to the powerful flexors, 
resulting in ‘clawing’) with subsequent loss of function (Figure 1.2). As a consequence of 
this a significant proportion of patients with DM will undergo major limb amputation, 
despite attempts at limb salvage or suffer complications relating to severe sepsis including 
myocardial infarction, renal failure and death (Jeffcoate 2006). 
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Figure 1.2: The natural history of diabetic foot ulceration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
These features can leave clinicians struggling to know which the most important 
components in the process are, but perhaps more importantly what the effects of treating or 
reversing these processes may have. Breaking this cycle requires action against each 
component: drainage of sepsis and debridement of necrotic tissue with appropriate 
antibiotic therapy, improved glycaemic control, pressure relief and in appropriate cases 
restoration of tissue perfusion.  
 
Although ischaemia can undoubtedly slow healing, many DFU will heal without vascular 
improvement [Elgzyri 2013] even in the presence of PAOD. The median time to DFU 
healing is reported to be 3-months (2-7months) [Leese 2007, Prompers 2008]. 
Consequently significant controversy exists within the surgical community regarding the 
role of very distal and infra-malleolar revascularisation in patients presenting with DFU, 
given the described multifactorial aetiology and the potential for improvement without 
revascularisation.  
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Identification of how significantly ischaemia as a consequence of PAOD may be 
contributing to DFU can be uncertain with current investigative strategies. Consequently 
identifying which patients may benefit from revascularisation, in terms of reversal of the 
natural history of the disease process remains poorly understood despite potentially being 
central to patient management. This clinical difficulty has been highlighted by systematic 
review of revascularisation for DFU, which reported a limb salvage rate of 80-85% 
[Hinchcliffe 2012, with ulcer healing occurring in only 60% (comparable to healing rates 
without intervention) [Leese 2007, Elgzyri 2013]. 
 
The National Institute of Clinical Excellence (NICE) has attempted to address this issue. A 
simple review question was asked - “when is the optimal time for surgical management 
(including vascular surgical reconstruction and orthopaedic interventions) to prevent 
amputation for diabetic foot problems?” A systematic search identified 9817 potentially 
relevant studies. However none of these met the inclusion criteria; as a consequence no 
consensus statement could be made [NICE 1993].   
 
To try and define the utility of revascularisation for patients with DFU we must first try to 
establish the significance of PAOD.  
 
1.3 Assessment of the peripheral arterial circulation of patients with diabetic foot 
Ulceration 
 
In much the same way as there is variation in the reporting of DFU [Chan 2015], there is 
variation in patient investigation and management. To be effective evaluation of DFU must 
be multifaceted. There is evidence demonstrating improved patient outcomes (reduction in 
both the rate of major limb amputation and the duration of hospital admission) if a 
multidisciplinary approach is adopted [NICE 2015]. Included in the assessment process 
must be an evaluation of the presence of sepsis, neuropathy, biomechanics of the foot and 
the presence of PAOD (in order to try and define whether there is ischaemia as a 
consequence of large vessel occlusive disease).  
 
Local vascular assessment includes clinical examination with some form of radiological 
imaging. However investigative algorithms vary between institutions and in other centres a 
variety of haemodynamic and/or biological assessments may be incorporated into this 
process.  
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1.3.1 Clinical assessment 
 
DFU may be broadly characterized into two groups – neuropathic and neuroischaemic. The 
neuropathic foot will typically be warm and well perfused, with palpable foot pulses, a 
reduction in hydrosis may be reported and there can be fissuring of the skin. The 
neuroischaemic foot will generally appear normal (although in some cases may appear 
hyperaemic as a consequence of arteriovenous shunting) and may be cool on palpation. 
There may be DFU. A history of intermittent claudication may be volunteered, which 
implies clinically significant PAOD, although in patients with DM (who will frequently 
have a more distal pattern of arterial disease – crural artery involvement [Strandness 1964, 
Hiatt 2001, Rueda 2008]) claudication may not be present. 
 
Arterial pulse palpation is the central component of clinical assessment of the peripheral 
circulation of the lower limb. Arterial pulse palpation will include assessment of the 
femoral pulse (common femoral artery), popliteal pulse (popliteal artery), posterior tibial 
pulse (posterior tibial artery) and dorsalis pedis pulse (dorsalis pedis artery – continuation 
of the anterior tibial artery). The presence (or absence) of a pulse gives the clinician an 
indication about the state of the circulation in the arterial segment above.  The sensitivity 
and reproducibility of proximal pulse palpation (femoral pulse) is 95% [Brearley 1992]. 
However the accuracy of distal pulse palpation would appear to be poor with under-
diagnosis in as many as 30%, false-positives and significant inter-observer variation 
described [Criqui 1985, Myers 1987, Brearley 1992, Lundin 1999]. 
 
Although the ‘character’ of a pulse is widely described, pulse character is not helpful in the 
context of assessment of the peripheral circulation. A binary assessment of ‘normal’ or 
‘abnormal/absent’ is likely to provide more consistent clinical information, with the latter 
implying a high probability of proximal PAOD [Jacobsen 1990], although clearly the 
burden of PAOD cannot be described from pulse palpation in isolation. 
 
Given that the clinical course of DFU is in many cases protracted, there may be a role for 
regular ulcer assessment whilst podiatry and dressing care is provided and more complex 
investigation is being performed. As a clinical predictor of wound healing, Sheehan has 
described the utility of serial ulcer measurement over a four-week period of intensive ulcer 
care [Sheehan 2003]. However there are significant limitations to this clinical assessment, 
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specifically the positive predictive value of healing was only 58%, whilst the negative 
predictive value was 91%. 
  
1.3.2 Non-invasive haemodynamic assessment  
 
The cornerstone of non-invasive vascular assessment of the lower limb is the 
ankle/brachial pressure index (ABPI), the principle for which was described by Windsor in 
1950 [Windsor 1950]. For the detection of POAD, defined as the presence of a 50% 
stenosis or more ABPI has a sensitivity of 79-95% and specificity of 90-96% (in the 
absence of diabetes)  [Carter 1968, Yao 1968, Lijmer 1996, Doobay 2005]. The Society for 
Vascular Technology has published a comprehensive laboratory protocol for assessment of 
ABPI, which aims to control the methodology by creating reproducible conditions [Cole 
2001].  
 
However there are a number of potential issues that can limit the accuracy of ABPI. If 
there is significant collateralization of the aorto-iliac segment some patients may have a 
normal resting ABPI even in the presence of significant proximal stenotic/occlusive 
atherosclerotic arterial lesions [Elhadd 1999]. Although there are well-defined protocols 
for assessment, ABPI may be recorded inconsistently through variability in methodology. 
Inter-observer variability has also been reported [Osmundson 1985, Simon 2000]. 
Furthermore determination of ABPI in patients with DM and PAOD is recognised as being 
less reliable than in patients without DM and PAOD [Raines 1976, Formosa 2013]. 
Pathophysiologically this is attributed to smooth muscle hypertrophy compounded by 
calcification of the media (there is increased ossification of the arterial wall due to 
increased expression of bone morphogenetic protein) leading to loss of arterial 
distensibility and increased vessel stiffness [Townsend 2008]. In the clinical context of 
minor amputation in patients with DM, ABPI in isolation has been described as a poor 
indicator for wound healing (or the potential requirement for arterial reconstruction) 
[Caruana 2015]. 
 
Toe pressures (TP) and the calculation of a toe brachial index (TBI) represent another non-
invasive means of assessing peripheral arterial pressure. It has been argued that in patients 
with DM TP/TBI may be more representative of the haemodynamic status of the limb than 
ABPI as the digital arteries are less likely to be effected by medial calcification. TASC 
define a TP of less than 30mmHg as indicative of critical limb ischaemia. A number of 
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studies have described the relationship of TP and wound healing. It has been suggested that 
no healing of primary forefoot amputations is seen if the TP is less than 38mmHg and that 
there are no failures of wound healing if the TP was 68mmHg, (or if the TP increased by 
30mmHg following revascularisation) [Larsson 1993, Vitti 1994]. However there is 
limited evidence validating this. Of the published work on TP/TBI in a normal study 
population only one of eight studies excluded asymptomatic PAOD by performing 
concurrent arterial imaging. From an epidemiological perspective ABPI is predictive as 
marker for cardiovascular morbidity and mortality, but with TP/TBI no firm conclusions 
can be drawn from the current literature [Høyer 2013]. Much of the published work 
describes assessment using the hallux (and more recently) the second toe [Bhamidipaty 
2015]. Whether similar changes are seen in the other toes of the foot is uncertain. Finally 
although much of the evidence describing TP/TBI seem to be compelling more recent 
work has questioned the accuracy of the current haemodynamic criteria to reflect patients 
at higher-risk of major limb amputation  [Vallabhaneni 2016] – this may be particularly 
relevant for patients with DM as the disease process seems to follow a different course 
from patients with PAOD in isolation [Leese 2007, Elgzyri 2013].  
 
1.3.3 Other tests of peripheral perfusion 
 
Pulse wave velocity evaluates changes in arterial pulse waves and is inversely related to 
the square root of the compliance of the vessel. Assessment of pulse wave velocity as an 
investigative strategy in patients with DM was described in 1962 [Woolam 1962]. It is an 
established technique that can be used to evaluate arterial compliance between two points 
in the arterial tree. There is some data to suggest that in the context of patients with POAD 
pulse wave velocity may correlate with ABPI and as such may be a valuable screening tool 
[Khandanpour 2006]. The investigation may augment haemodynamic assessment with 
ABPI/TBI and help identify a patient population at higher risk of cardiovascular events 
[Sutton-Tyrrell 2005]. However there is no high quality contemporary evidence that it has 
predictive value with regard to DFU healing.  
 
Skin auto fluorescence is another non-invasive investigative tool that can predict vascular 
insufficiency in patients with type II DM [Lutgers 2006]. The technique of skin auto 
fluorescence has been linked to the formation of advanced glycosylation end products, 
which are increased in diabetes [Brownlee 2001] and which have a deleterious effect on the 
arterial wall. As with pulse wave velocity this investigation can help to identify a 
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population at risk of cardiovascular events [Meerwaldt 2005], but there is no evidence to 
support predictive value with regard to DFU healing.  
 
Hyperspectral technology (HT) is a diagnostic tool that can quantify tissue oxygenation 
and has been shown to detect systemic and local microcirculatory changes associated with 
diabetes. Khaodhiar et al describe HT as an accurate predictor of ulcer healing (although it 
must be noted that their study included only a small number of patients with Type I DM 
and patients with POAD were excluded) [Khaodhiar 2007].  There is some conflicting 
evidence as to the utility of HT in patients with PAOD [Jafari-Saraf L 2010, Chin 2011] 
and the technique requires further clinical validation before it may be used safely and 
effectively in a clinical setting. 
 
Transcutaneous oxygen tension measurement (TcPO2) is a non-invasive investigative 
modality that can be used to assess the partial pressure of oxygen at the surface of the skin. 
The normal oxygen tension in the foot is 60mmHg. TcPO2 has been investigated in patients 
with PAOD, with and without DM [Wyss 1984]. In both groups TcPO2 measurements of 
less than 20mmHg were associated the presence of ulceration and a potential requirement 
for major limb amputation. However patients with DM were more likely to have ulceration 
with TcPO2 greater than 20mmHg, confirming (as previously described) the multifactorial 
nature of DFU.  
 
Subsequent studies with relatively small groups of patients have suggested TcPO2 mapping 
may have a role in defining the patient population with DFU who have a significant 
ischaemic component as a consequence of PAOD that could potentially be modified to 
alter the natural history of the disease process [Ballard 1995] and possibly prediction of 
DFU ulcer healing [Kalani 1999]. A potential confounding issue is that TcPO2 in patients 
with DM, but without PAOD is lower than is found in age/sex-matched controls [Meijer 
2008] and is consequently this technique is not specific to PAOD.  
 
1.3.4 Radiological imaging 
 
Radiological imaging provides robust anatomical information with regard to the burden, 
morphology and pattern of PAOD and is essential to plan intervention – it does not allow 
meaningful assessment of distal perfusion. Interpretation of arterial imaging in the DM 
cohort is challenging – frequently there is multi-level arterial disease and as has been 
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previously described there is often an infra-geniculate pattern to this [Strandness 1964, 
Rueda 2008]. These arteries are of small calibre and the combination of calcification of 
atherosclerotic plaque with concurrent medial calcification, results in challenges with 
interpretation. 
 
Duplex ultrasound is a non-invasive, inexpensive strategy that obviates the requirement for 
potentially nephrotoxic contrast media. Duplex ultrasound can provide accurate anatomical 
information [Eiberg 2010] particularly in relation to the supra-geniculate circulation. 
Assessment of the proximal tibial vessels can be more challenging, particularly if there is 
significant calcification. Sequential stenoses as is often encountered in patients with DM 
can contribute to making assessment of the more distal circulation challenging. With this 
imaging modality there is also potential for inter-observer variability [Ubbink 2001].  
 
The evolution and progression of Computed Tomography angiography (CTA) with multi-
detector spiral scanners has made high quality angiography possible. As the technology has 
evolved acquisition times have shortened and with improvements in resolution and the use 
of advanced post-processing techniques image quality has improved. The technique 
requires the administration of iodinated contrast and consequently there is a risk of 
contrast-induced nephropathy, which appears to be most significant in patients with a 
diagnosis of DM and diabetic nephropathy, with pre-existing biochemical renal 
dysfunction [Parfrey 1989, Waybill 2001]. With this imaging modality sensitivity and 
specificity appear to be better for arterial occlusions than stenoses, with little inter-observer 
variability for lesions in the aorto-iliac and femoro-popliteal segments. As with duplex 
ultrasound assessment of the crural circulation can be more challenging. As previously 
described these are small calibre arteries and the combination of this with medial 
calcification and calcification of atherosclerotic arterial plaques can make assessment of 
vessel patency challenging [Fleischmann 2006].   
 
Magnetic resonance angiography (MRA) can provide high quality arterial imaging using 
either a contrast enhanced approach or by using non-contrast enhanced, flow sensitive 
techniques, so called ‘time of flight’, that is effective by measuring the different signal 
properties between static tissue and flowing blood. The high quality images that can be 
derived must be balanced against the expense of the investigation, which is time 
consuming and which many patients find claustrophobic. Again there can be issues with 
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tibial vessel resolution – there is a shorter time difference between the arterial and venous 
enhancement, which can result in significant venous contamination [Pollak 2012].  
 
Digital subtraction angiography dates back to the 1970’s and the evolution of this 
technique has been credited to the department of clinical radiology in the Cleveland clinic. 
The technique is invasive (requiring percutaneous arterial access) and a contrast load must 
be given (this can take the form of either iodinated contrast – where there is the potential 
for renal dysfunction as has been described above, alternatively carbon dioxide may be 
used). The investigation also requires exposure to radiation (to both the patient and the 
clinical team involved). Many still consider this to be the ‘gold-standard’ arterial 
investigation [Pomposelli 2010], as it has both diagnostic utility and offers the potential to 
perform endovascular intervention (angioplasty and/or stenting). Imaging of the crural 
circulation and pedal arteries with this investigation is excellent.   
 
The Angiosome concept merits consideration at this stage. The ankle and foot may be sub-
divided into six distinct geographical territories, supplied by the posterior tibial, peroneal 
and anterior tibial arteries. The concept has attracted interest particularly in patients with 
DFU. There is some evidence in the published literature supporting a strategy of direct 
revascularisation of the source artery whenever appropriate, rather than relying on 
collateralization [Attinger 2006, Alexandrescu 2008, Neville 2009]. However the general 
quality of the evidence available is poor. Published data has generally been derived from 
single institutions and has been analysed retrospectively. To date there are no prospectively 
collected data available to validate the reported series.  
 
1.4 Biomarkers in cardiovascular disease 
 
A biomarker may be defined as a measurable indicator of the presence or severity of a 
disease process. To be effective a biomarker must be both sensitive and specific to the 
disease process being investigated. It should be easy to measure and the result should offer 
a meaningful impact upon the management of the condition. Ideally the test should also be 
inexpensive. The best example of an effective biomarker in current practice is serum 
troponin assay for the detection of myocardial ischaemia. The investigation has been 
widely adopted in contemporary clinical practice as it can be measured rapidly and 
provides useful prognostic information with early identification of patients at higher risk of 
cardiac death [Antman 1996].  
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A series of biochemical markers have been identified which reflect endothelial dysfunction 
and appear to be influenced in the context of both the ischaemic and neuropathic diabetic 
limb. These include von Willebrand Factor (vWF), Vascular Endothelial Growth Factor 
(VEGF), Homocysteine, Endothelin-1, Vascular Adhesion Molecule, Thrombomodulin 
and E-selectin. It is hypothesised that the production of these is potentiated by oxidative 
stress in the context of white cell activation and reactive oxygen species [Hickman 1994, 
Woodman 2002]. Hyperinsulinaemia and hyperglycaemia appear to have no apparent 
effect on release of these biochemical markers [Kessler 2001, Oomen 2002].  
 
vWF is an acute phase protein. Plasma vWF is proposed to be a marker of endothelial 
dysfunction as it is predominantly synthesised by endothelial cells, which normally 
account for more than 85% of vWF in circulating blood, along with equimolar amounts of 
pro-peptide (vWF:AgII) [Vischer 1998]. There is some evidence to support the hypothesis 
that vWF is a marker of platelet activation, as in pathological conditions it may also be 
released by platelets [Mannuci 1998]. Plasma vWF is increased in patients with lower limb 
ischaemia, but is also elevated in patients with DM and neuropathic lower limb ulceration, 
relative to case matched controls. This appears to be independent of PAOD [Blann 1995] 
and may rather represent endothelial dysfunction, previously referred to as ‘microvascular’ 
or ‘small vessel disease’.  
 
Nitric oxide (NO) is a free radical synthesised from L-Arginine by the enzyme nitric oxide 
synthase. It is a vasodilator secreted by endothelium. As the half-life is short, indirect 
measures of NO are made by assessment of plasma or urinary nitrates/nitrites. Insulin 
stimulates NO production through the endothelial insulin receptor, with lack of insulin, or 
insulin resistance potentially depressing NO production [Zeng 1996]. In wounds NO is 
produced by macrophages, fibroblasts and endothelium. Jude et al have made several 
interesting observations relating to the presence of increased NO in diabetic patients with 
ulceration/healed ulceration relative to diabetic patients without ulceration [Jude 1999]. 
They also postulate that NO may be involved in the progression of DFU [Jude 2001].  
 
Tissue factor (TF) is a key initiator in the coagulation cascade and has a critical role in the 
propagation of thrombus. Elevated levels of TF have been demonstrated in patients with 
DM [Zumbach 1997] and it is postulated that a hypercoaguable state may be associated 
with adverse outcomes [Soejima 1999]. 
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C-reactive protein (CRP) is a pentameric protein synthesised in the liver in response to 
interleukin-6 (IL-6), but is also synthesised in smooth muscle cells of atherosclerotic 
plaques [Khawaja 2009]. CRP is associated with down regulation of NO synthase, 
increased expression of Cellular Adhesion Molecules (CAMs), activation of the 
compliment system, up regulation of LDL phagocytosis by macrophages and vascular 
smooth muscle migration, proliferation and neo-intimal formation. CRP is a marker of 
vascular inflammation and plaque instability [Khawaja 2009], and several studies including 
the Rotterdam [Van der Meer 2002] and Edinburgh Artery study [Tzoulaki 2002] have 
implicated an elevated CRP in the progression of arterial disease. 
 
Interleukin-6 (IL-6) is an inflammatory cytokine, which is produced by hepatocytes, 
lymphocytes and endothelial cells. As previously described it is the stimulus for the 
production of CRP and in the Edinburgh Artery Study was found to be the strongest 
biochemical indicator of progressive arterial disease [Tzoulaki 2005]. 
 
It is not clear whether these biochemical markers can meaningfully help identify the 
patient population with DM at greatest risk of complication, or those that may benefit from 
revascularisation. There seems to be an association between insulin resistance and 
endothelial dysfunction and it may be that an increase in endothelial markers such as 
endothelin-1 and vWF may precede the development of ulceration [Stehower 1996, 
Seligman 2000]. In a series of patients with type II DM, Lim et al demonstrated a 
significant reduction in vWF with multi-factorial pharmacological intervention in patients 
with no pre-existing cardiovascular disease [Lim 2004]. Similarly it would appear that 
major limb amputation in the context of critical limb ischaemia leads to reduction in vWF 
as well as VEGF [McLaren 2002, Newton 2008]. It is not clear whether these changes may 
be seen in patients undergoing revascularisation procedures. Tsai et al describe the effect 
of lower limb bypass in 21 patients with critical limb ischaemia and type II DM on plasma 
concentration of endothelin-1 and nitric oxide and found no significant differences pre- 
and post-revascularisation surgery  [Tsai 2009]. It seems unlikely that these markers have 
the specificity or sensitivity to be useful in a prediction model for patients with DFU. 
These changes may be useful for monitoring or biochemically assessing the impact of an 
intervention, but they will not provide any prognostic information with regard to the 
outcome of DFU and as such it would seem that at best they have limited clinical utility in 
this setting. 
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Fundamentally CLI as a consequence of PAOD is a disease of the skin of the foot [Rossi 
2004]. As such it would seem that the most appropriate place to identify a biomarker of 
ischaemia in the context of DFU is the skin of the foot. 
 
1.5 Connexins 
 
1.5.1 Connexin Biochemistry and the Gap Junction 
 
Gap Junctions (GJ) directly link the cytoplasm of adjacent cells. They facilitate inter-
cellular communication and are integral in the maintenance of cellular homeostasis. Since 
the discovery of GJ numerous studies of structure and function have been performed 
[Caspar 1977, Makowski 1977, Makowski 1982, Maeda 2011]. It has become clear that GJ 
are integral in the control of cellular differentiation and growth, whilst also representing an 
important mechanism for apoptosis and spreading death signals between cells (Talhouk 
2008, Bargiotas 2009).  
 
The single transmembrane protein subunits of GJ are the Connexin proteins (Cx). Twenty-
one different human Cx have been identified each with a unique amino-acid sequence and 
specific biochemical properties. The genes encoding for Cx tend to occur in clusters 
around certain chromosomes, sharing a common structure, consisting of two exons 
separated by one intron sequence.  
 
The Cx protein is composed of nine principle domains. The N-terminus, two extracellular 
loops (EL1 and EL2), stabilized by intra-molecular disulfide bridges, and four 
transmembrane domains, which are highly conserved among different isoforms. The intra-
cellular amino acid terminus is of similar length in all Cx. The major difference between 
Cx is the length and sequence motifs of the carboxyl tail, which are divergent allowing for 
functional differences between the different Cx and the connexon types [Evans 2002, 
Dbouk 2009]. The precise purpose of multisite phosphorylation of the carboxyl tail is 
unclear. They access the cytoplasmic reticulum and bind other structural proteins, a 
process which is crucial for synchronized cellular communication.  
 
Cx nomenclature is based on molecular weight; for example, Cx43 is a 43 kiloDaltons 
(kDa) protein [Beyer 1987]. A second method of nomenclature is based on the sequence 
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similarity and length of the cytoplasmic loop (CL). This latter methodology separates Cx 
into four main groups (alpha, beta, delta and gamma) [Eiberger 2001]. 
 
Regulation of Cx expression is effected at different levels from transcription to the post-
translational processes although the mechanisms involved are poorly defined. It has been 
suggested that microRNA (mRNA) species may be key regulators of Cx expression. Cx 
are synthesised in the endoplasmic reticulum, where they are rapidly oligomerised to form 
hexameric connexons (CxHc). This process is completed within the Golgi apparatus, 
following which the connexon is trafficked to assemble in the lipid milieu of the plasma 
membrane (a calmodulin dependent step). The polymeric assemblies of aligned pairs 
results in the formation of GJ.  
 
Cx proteins have a very short half-life not exceeding few hours [Solan 2009], the synthesis 
and delivery to the membrane of new Cx proteins is coupled to simultaneous gap junction 
internalization and Cx degradation [Segretain 2004]. The entire GJ or fragments of the GJ 
internalise as double membrane structures, with their final fate being a merger with 
lysosomes where they are degraded – breakdown of channels occurs via endocytosis and 
degradation [Salameh 2006]. 
 
CxHc are arranged into dynamic, spatially and temporally organised aggregates, which at 
the ultra-structural level are identified by their electron dense pentalaminar structure 
[Hanner 2010]. These are often described as plaques [Segretain 2004], with a single plaque 
containing anything from a few, too many thousands of individual channels. These plaques 
can facilitate the rapid propagation of action potentials and the direct diffusion of inorganic 
ions, ATP, cAMP, and other small water-soluble molecules (<1.0-2.0 kDa) between cells.  
 
The structure of the GJ channel pore is critical to understanding the molecular mechanisms 
underlying selective permeation and voltage-dependent gating of channels formed by the 
Cx family [Tang 2009]. The capacity of different Cx isoforms to respond uniquely to 
similar stimuli and thereby alter the selectivity and permeability properties of GJ is a key 
concept in understanding Cx-specific functional roles and an important reason for the large 
number of Cx isoforms and their co-expression [Harris 2007, Heyman 2009]. 
 
Cx expression, hemichannel function and GJ channel activity are closely regulated. This is 
mediated by growth factors and pro-inflammatory mediators such as peptidoglycan (PGN), 
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lipopolysaccharide (LPS) and the cytokines [Chanson 2005]. Cytokines may have a role in 
gene expression, stability of Cx mRNA and protein degradation. Although pro-
inflammatory cytokines exacerbate cellular damage, they also have an important role in 
tissue repair by stimulating apoptosis and cell proliferation. At a molecular level the effects 
of these substances is termed 'channel gating' [Anand 2005, Chanson 2005]. The term 
gating has been defined as the mechanism by which the movement of ionic or non-ionic 
species becomes physically restricted because of the channel itself. Gating may also induce 
a conformational change of a channel protein, a reversible process where a complete or 
relative closure or opening of a channel occurs [Moreno 2005, Moreno 2007]. The 
domains involved in Cx channel gating include the carboxyl and amino-termini, as well as 
the extracellular domains. Inducers include electrical current and chemical changes (pH, 
protein phosphorylation and intra/extracellular Calcium). The diverse actions of 
phosphorylation may induce a variety of modulation and gating properties in cells. 
 
Under normal conditions GJ channels are open. Conversely CxHc generally remain in a 
closed configuration but may be induced to open by a variety of stimuli (such as removal 
of extracellular calcium, hypoxia, mechanical stress and dephosphorylation), with a 
subsequent release of ATP, which may then mediate autocrine or paracrine signaling via 
purinergic receptors [Bader 2006]. CxHc have a functional capacity out-with GJ formation, 
as they represent large unopposed membrane pores that connect the intra and extra-cellular 
compartments. These hemichannels can be induced or opened by elimination of 
extracellular calcium or inhibition of the electron transport chain. Of potential 
pharmacological relevance is that CxHc may be blocked by the peptide gap junctional 
inhibitors [Figeuroa 2006].  
 
1.5.2 Connexin 43 
 
Cx43 is broadly expressed and is the most abundant of the Cx being present in in at least 
34 tissues and 46 cell types [Zimmerli 2007, Wright 2009, Solan 2009]. There are sixteen 
sites on the carboxyl terminus of Cx43 that may be phosphorylated. Figure 1.3 provides a 
schematic representation of Cx43 [Schulz 2015]. 
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Figure 1.3: Connexin 43 [Schulz 2015] 
 
 
 
In cultured fibroblasts initial phosphorylation of Cx43 may occur within 15 minutes. A 
basal degree of phosphorylation seems to be required on five of the serine residues of Cx43 
for the assembly and functioning of GJ. Most Cx are phosphorylated in vivo, primarily on 
the serine and to a lesser extent on the threonine and tyrosine residues of the carboxyl 
terminus [De Vuyst 2007].  
 
Serine368 is a major site of phosphorylation on Cx43 in vivo. PKC mediated 
phosphorylation of the Serine368 of Cx43 [Cx43(Ser368)] is a major mechanism by which 
TPA disrupts cellular communication (Lampe 2000). Activation of several kinases 
including protein kinase A (PKA), protein kinase C (PKC), p34(cdc2)/cyclin B kinase, 
casein kinase 1 (CK1), mitogen-activated protein kinase (MAPK) and pp60(src) kinase can 
lead to phosphorylation of the majority of the 21 serine and two of the tyrosine residues in 
the C-terminal region of Cx43 [Solan 2005]. 
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1.5.3 Connexin/Gap Junction Expression in Skin and Wound Healing 
 
Growth control and maintenance of a homeostatic equilibrium in the mature mammalian 
epidermis is manifested morphologically by a constant thickness of epidermal cell layers. 
Cells within the basal layer of the skin represent the proliferative population, supplying 
cells that move into the supra-basal layers and undergo a specific and coordinated 
program of differentiation (including the expression of the substrates involucrin and 
loricrin and the cross linking enzyme transglutaminase). 
 
The epidermis is primarily composed of keratinocytes that temporally and spatially 
express up to 10 different Cx types depending on the degree of differentiation.  
Cx43 is ubiquitously found in all epithelial layers of ectodermal origin [Richards 2005]. 
There is focal distribution of Cx43 expression in the basal keratinocytes (stratum basale), 
with the suprabasal cells (stratum spinosum) demonstrating higher expression [Richard 
2000, Brandner 2004]. Cx43 expression in normal proliferating keratinocytes falls both at 
the mRNA and protein level in non-dividing cells (post-confluent cells) [Gibson 1997]. 
 
Butterweck and co-workers have used a murine model to investigate epidermal and 
follicular development and differentiation, demonstrating that the development of healthy 
skin coincides with multiple differential Cx expression [Butterweck 1994]. The co-
expression of multiple different Cx from the same keratinocyte, with co-localisation at 
GJ suggests that the epidermis can form communication compartments with different 
regulatory properties [Risek 1998]. Direct intercellular signaling, controls keratinocyte 
behaviour, proliferation and differentiation, occurs through gap junctions. 
 
The GJ of human keratinocytes predominantly express Cx43, which is abundantly 
expressed within the interfollicular epidermis and is involved in the complex process of 
keratinocyte differentiation [Saloman 1994, Gibson 1997, Wiszniewski 2000]. In the 
undifferentiated epidermis Cx26 and Cx43 are co-expressed and differentially regulated 
during the differentiation of tissue. Previous studies have not demonstrated the presence 
of Cx26 in the fully differentiated epidermis [Saloman 1994]. The maintenance of an 
established epidermis does not seem to be affected by Cx availability. 
 
Wound healing is a complex process involving four main phases - haemostasis, 
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inflammation, proliferation and remodeling [Chin 2011]. The inflammatory cascade 
initiated results in a variety of cells migrating into the wound (including the neutrophil, 
which releases oxygen free radicals and secretes pro-inflammatory cytokines and 
macrophages, which are major producers of cytokines, chemokines and growth factors 
that direct subsequent cell migration). Thereafter, subsequent remodeling and scar 
differentiation involves multiple cell types in a predictable and overlapping sequence of 
cellular events that includes inflammation, migration/proliferation and extracellular 
matrix deposition [Rhett 2008].  
 
GJ expression is altered at sites of inflammation in vivo and could thus contribute to 
pathophysiological responses. Cx expression is tightly regulated after skin injury, at the 
transcriptional, translational, and post- translational levels. Cx43 would seem to be 
central to this process, with Langlois and colleagues describing dysregulation of 
keratinocyte differentiation resulting from changes in Cx expression (Langlois 2007).  
Prior to GJ formation, under specific physiological conditions Cx may be induced to 
open and release paracrine messengers into the extracellular space. In this context Cx 
have a role in the proliferation, migration and differentiation of keratinocytes and 
fibroblasts. Subsequent signaling via the extensive GJ network found in skin [Goliger 
1995] and from within communication compartments of the advancing epithelium is 
proposed to play a central role in the repair process [Wang 2007]. The extensive 
interaction between keratinocytes and fibroblasts during this stage of the healing process 
is fundamental and correlates with changes in Cx expression [Abdullah 1999].  
 
Epidermal cells at the wound edge undergo several phenotypic alterations called 
keratinocyte activation to permit migration across the wound. Approximately 24-48 
hours after injury cells at the wound edge become hyper-proliferative and generate 
additional migratory cells [Goliger 1995]. Following injury, spontaneous epidermal 
regeneration occurs over a five to seven day period. A role for GJIC in the wound healing 
process was postulated by Gabbiani et al, who demonstrated with electron microscopy, 
that epithelial cells at the periphery of a healing wound have nearly four times the surface 
area occupied by GJ than normal cells [Goliger 1995]. This is perhaps unsurprising given 
that Cx have been implicated in a variety of different dermatological diseases (keratitis-
ichthyosis deafness syndrome, erythrokeratoderma variabilis, Vohwinkel's syndrome). 
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Down-regulation of Cx43 in the basal layer cells of the epidermis may favour the 
transformation or de-differentiation of keratinocytes into the migrating phenotype [Kretz 
2003]. In the proliferative phase expression and phosphorylation of Cx43 at the wound 
edge then increases [Chin 2011], with an increase in the expression and phosphorylation 
status at Cx43(Ser368) in adjacent basal cells [Solan 2009]. By seventy-two hours the 
levels and distribution of Cx43(Ser368) have returned to normal.  
 
1.5.4 Influence of diabetes on Connexin expression in skin and wound healing 
 
“Hyperglycaemic memory” is a phenomenon where, even after glycaemic control has 
been re-established in a diabetic patient, the effects of the prior hyperglycaemia insult 
continue to develop. The onset of diabetes has a marked effect on the expression levels of 
Cxs in the skin, an effect that is more pronounced when the skin is injured. The 
mechanism whereby diabetes alters the expression of Cxs, with a differential effect on 
different Cx proteins has not been fully explained. 
 
Both high glucose and oxidative stress in-vitro have been shown to alter Cx expression 
and/or gap junctional communication in a variety of different cell types [Wang 2007, 
Ball 2011, Pollock 2011]. In the hyperglycaemic state mRNA transcription demonstrates 
increased expression of Cx26, Cx30.3, Cx31.1 and Cx43 [Bajpai 2011]. The 
hyperglycaemic state influences PKC activation and through this metabolic pathway may 
have different effects on Cx43 [Malfait 2001].  
 
In diabetes, impaired wound healing and ulceration, by glycation of extracellular matrix 
compounds, inhibit cellular migration and increase sensitivity of fibroblasts to growth 
factors [Pollock 2011], with delayed entry into the wound site and a reduction in collagen 
production [Abdullah 1999]. Hyperglycaemia has a directly detrimental affect on the 
migration of epidermal keratinocytes and dermal fibroblasts, with evidence from in vitro 
models suggesting that this may be the result of down regulation of Cx43 expression, 
although this does not appear to be uniform and may be a direct consequence of the 
diabetic condition rather than a secondary consequence, or complication of long-term 
diabetes. There is some evidence that this inhibition may be due to an increase in protein 
kinase C phosphorylation [Wang 2007, Tyml 2011]. 
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In healthy skin Brandner and co-workers have evaluated the keratinocytes in human 
subjects with and without diabetes. The biopsies were taken from a proximal site (from a 
level at which there was unlikely to be arterial insufficiency). The expression of Cx26 
was no different between individuals with and without diabetes (skin biopsy) and there 
was no statistical difference in the expression of Cx43 mRNA between DM and non-DM 
subjects [Brandner 2008]. 
 
Persistent abnormal up-regulation of Cx43 in DM has been demonstrated in animal 
models [Wang 2007]. This has also been demonstrated in chronic non-healing wounds 
and in the epidermal wound edges of chronic diabetic ulcers in humans [Wright 2009]. 
Following injury the Cx43 levels in diabetic skin increase rather than down-regulate 
(down-regulation in diabetes seems to be delayed by at least forty-eight hours). The 
keratinocytes in diabetes seem to form a 'thick bulb' with a delay in adopting a migratory 
morphology [Chin 2011]. The behaviour of fibroblasts and expression of Cx43 and Cx26 
in DM and non-DM skin seems to be similar [Abdullah 1999]. 
 
1.5.5 Connexin 43 and ischaemia 
 
Ischaemia may be defined as a complex insult comprising of hypoxia, acidosis, local and 
systemic metabolic changes and leading to ATP depletion at a cellular level. The effect of 
ischaemia on Cx expression has been investigated in the cardiac myocyte and 
myofibroblast, but has not been fully defined in skin. There is evidence to suggest 
differences in Cx43 expression in response to ischaemia. Prolonged hypoxia in cardiac 
models down-regulates Cx43 GJs (reduction of 50% at 5 hours) and there is a total 
reduction of cellular Cx43 [Zeevi-Levin 2005]. However there appears to be a rapid 
increase in phosphorylation of Cx43(Ser368) [Solan 2007]. From a functional perspective 
ischaemic conditions influence both hemichannel and GJ function (for example metabolic 
inhibition may open Cx43 hemichannels, where-as ischaemia may induce GJ closure) 
[Johansen 2011].  
 
Consequently in the cardiac myocyte hemichannel opening in response to ischaemia may 
be a factor in the development of cell death through alteration in membrane properties as a 
result of ionic dysregulation (calcium loss), loss of metabolites and changes in intracellular 
ATP [Shintani-Ashida 2007, Talhouk 2008, Bargiotas 2009]. The phosphorylation status 
of the carboxyl tail amongst other factors may regulate this. Cx43(Ser368) is a major 
 
 
 39 
protein kinase C phosphorylation site. In the cardiac myocyte it seems to be involved in 
ischaemic pre-conditioning, by delaying dephosphorylation (Johansen 2011). It is not clear 
what role this may have in human skin. 
 
1.5.6 Connexin 43(Serine 368) as a biological marker of ischaemia in skin 
 
Previous work has demonstrated the presence of Cx43(Ser368) in healthy skin of the lower 
leg – with significant up regulation of Cx43(Ser368) 24 hours following mechanical 
wounding (punch biopsy) [Richards 2004].  Cardiac myocyte work implies down 
regulation of Cx43 and up regulation of Cx43(Ser368) in response to ischaemia in the 
cardiac myocyte [Johansen 2011].  
 
Consequently the hypothesis for this study was that Cx43 and Cx43(Ser368) protein 
expression would be modified in response to ischaemia in human skin 
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1.6 Study Aims 
 
i. To determine whether UoT classification on the first presentation for a 
particular limb, carried clear prognostic significance in terms of major adverse 
clinical events, namely hospital admissions for sepsis, the need for arterial 
reconstruction or amputation (minor and major), ulcer recurrence and death.   
 
ii. To investigate in vivo the expression of Cx43 and Cx43(Ser368) in full 
thickness skin biopsies from patients with severely symptomatic PAOD (with 
and without DM) and in a control group  
 
iii. To establish in vitro how protein expression of Cx43 and Cx43(Ser368) in 
human keratinocytes and fibroblasts (cultured from patients with PAOD, with 
and without DM and a control population without occlusive arterial disease) is 
influenced by hypoxia 
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Chapter 2 – The University of Texas Classification of Diabetic Foot Ulceration 
 
2.1 Description of the University of Texas classification, the value of scoring systems 
in diabetic foot ulceration and aims of the present work 
 
The process of attaining and maintaining a healed state in patients with DFU remains 
incompletely understood, but a multidisciplinary approach is clearly beneficial [NICE 
2015].  Early identification of patients with poorer prognoses and at higher risk of major 
adverse clinical events may be helpful. A number of DFU scoring systems have been 
developed for this purpose [Jeffcoate 1993, Lavery 1996, Mills 2014]. As well as having 
prognostic significance, scoring systems aid inter-disciplinary communication. Regardless 
of the scoring system used, simplicity and reproducibility are essential [Teasdale 1974]. 
 
The University of Texas (UoT) diabetic foot score has two components, the first describing 
ulcer depth and the second the presence of sepsis and/or peripheral arterial occlusive 
disease (PAOD), defined on clinical grounds. The latter are potentially correctable, and 
correction may influence the natural history of the individual ulcer and the outcome for the 
affected limb. The UoT scoring system has been retrospectively validated and a significant 
association observed between ulcer depth and the presence of infection and/or ischaemia 
with major limb amputation [Armstrong 1998].   
 
Surgeons often become involved in the care of DFU, but frequently this is only after major 
complications have developed. The UoT classification applied at first presentation may 
have a role in alerting the multidisciplinary team to limbs at greatest risk, not just of 
amputation, but also of recurrent ulceration and infection. Targeting these limbs with early 
investigation and more aggressive management of ischaemia and sepsis may improve long-
term outcomes. Consistency of DFU classification with UoT would improve 
communication between the different members of the multidisciplinary healthcare team.  
 
The aim of this chapter was to determine whether UoT classification on the first 
presentation, carried clear prognostic significance in terms of major adverse clinical 
events, namely hospital admissions for sepsis, the need for arterial reconstruction or 
amputation, ulcer recurrence and death.   
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2.2 Summary of patients and methods 
 
The South Glasgow diabetic foot clinic database was established in 2005. Data were 
entered at first presentation and all subsequent clinic attendances. Recorded data included 
patient demographics, estimated date of onset of the ulcer(s), site of ulceration and 
classification according to the UoT scoring system. The data for patients entered between 
May 2005 and August 2013 were used. Median patient follow-up was 3.5 years. Follow-up 
data were retrieved from the primary database and supplemented using local and national 
electronic patient record systems through case-linkage using the Community Health Index 
(CHI) number [Stuart 2013].  
 
All patients presenting to the diabetic foot clinic with DFU were considered eligible for 
inclusion. For this analysis, the UoT classification at the first presentation to the diabetic 
foot clinic was used. If there was more than one ulcer at presentation, the highest scoring 
ulcer was used to classify the individual limb. Patients attending the clinic with Charcot 
change without concurrent ulceration were excluded from analysis.  
 
For UoT classification, ulcer depth was ascertained by probing, ischaemia diagnosed 
clinically based on the absence of foot pulses and sepsis defined using previously validated 
clinical criteria (more than one sign of local inflammation or the presence of purulent 
discharge) [Lavery 2007]. Assessment was performed and recorded by different members 
of the multidisciplinary team; including diabetologists, podiatrists, specialist nurses and 
vascular surgeons.   
 
Major adverse clinical events (MACE) were defined as hospital admissions for sepsis 
(both medical management and surgical drainage), arterial reconstruction (endovascular or 
surgical), lower extremity amputation (defined as any loss of the limb in the transverse 
plane; infra-malleolar procedures were defined as minor amputations and supra-malleolar 
amputations as major amputations – [Kennon 2012]) recurrent ulceration and death during 
the follow-up period.  
 
Data were analysed by limb. Summary data are expressed as mean and standard deviations 
(SD) or median and interquartile range (IQR). Statistical analysis was performed using 
SPSS (version 21). Comparison of groups was performed with Chi-square test (a P-value 
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of less than 0.05 was considered significant). Survival analysis was performed using 
Kaplan-Meier methodology, with the Chi-square test used to compare the curves. 
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2.3 Results 
 
Details of 388 patients with 515 symptomatic limbs were entered into the database during 
the study period. Eight patients were excluded from analysis as they presented with 
Charcot change without active ulceration. From the remaining 507 limbs there were 971 
ulcer episodes during the study period.  
 
Median patient age was 66-years (inter-quartile range 54 to 77-years) and 230 patients 
(59.3%) were men. In 130 (25.2%) cases the patient had multiple ulcers on the index foot 
at the time of presentation. In 200 cases (38.8%) ulcers occurred at more than one 
anatomical site on the same foot during follow-up. At presentation 52 (13.4%) patients had 
bilateral foot ulceration. By the end of the follow-up period 125 (32.2%) patients had 
developed ulceration affecting both feet. 
 
In 432 (85%) cases the ulcer was defined as superficial and in 230 (45%) cases neither 
sepsis nor ischaemia were present at the time of the first assessment (Table 2.1). There 
were only 12 cases where re-assessment of the initial DFU resulted in the UoT score being 
changed to indicate more severe disease.   
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Table 2.1 University of Texas classification of index ulcer on primary presentation 
 
 
 
Depth 0 
(Epithelialised) 
n=63 
Depth 1 
(Superficial) 
n=369 
Depth 2  
(Tendon/joint capsule) 
n=21 
Depth 3  
(Bone/joint) 
n=54 
Stage A  
(No sepsis/Pulses 
present) 
n=230 
 
55 
 
170 
 
1 
 
4 
Stage B  
(Sepsis/Pulses 
present) 
n=75 
 
1 
 
50 
 
8 
 
16 
Stage C  
(No sepsis/Pulses 
absent) 
n=148 
 
7 
 
119 
 
11 
 
11 
Stage D  
(Sepsis/Pulses 
absent) 
n=54 
 
0 
 
30 
 
1 
 
23 
 
 
Major adverse clinical events are summarised in Table 2.2. Deeper ulcers at presentation 
were associated with significantly higher rates of amputation (both minor and major) and 
arterial reconstruction (Figure 2.1). With progression in the stage of UoT score there was a 
significant increase in both rates of major limb amputation and arterial reconstruction 
(Figure 2.2). 
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Table 2.2 Summary of Major Adverse Clinical Events  
 
 Minor 
amputation 
Major 
amputation 
Revasc*  Recurrence Sepsis Death MACE 
0A (55) 1  
(2%) 
1  
(2%) 
1  
(2%) 
10  
(18%) 
7 
(13%) 
9 
(16%) 
15  
(27%) 
0B (1) 0 1 0 0 1 0 1 
0C (7) 0 1 0 1 3 0 3 
0D (0) - - - - - - - 
1A (167) 12  
(7%) 
8 
(5%) 
6  
(3.5%) 
33 
(20%) 
40 
(24%) 
39 
(23%) 
74  
(44%) 
1B (52) 4  
(8%) 
2  
(4%) 
3 
(6%) 
12  
(23%) 
15 
(29%) 
6 
(12%) 
25  
(48%) 
1C (118) 7  
(6%) 
8  
(7%) 
16  
(14%) 
19  
(16%) 
32 
(27%) 
47 
(40%) 
57  
(48%) 
1D (30) 2  
(7%) 
6  
(20%) 
10  
(33%) 
17  
(57%) 
13 
(43%) 
9 
(30%) 
16  
(53%) 
2A (1) 0 0 0 0 1 0 1 
2B (8) 3 0 0 3 3 1 6 
2C (11) 3  
(27%) 
3  
(27%) 
6  
(55%) 
6  
(55%) 
4 
(36%) 
6 
(55%) 
8  
(73%) 
2D (1) 0 1 0 0 1 0 1 
3A (4) 1 0 0 1 2 1 4 
3B (16) 3 
(19%) 
2  
(12%) 
0 4  
(25%) 
8 
(50%) 
4 
(25%) 
13 
(81%) 
3C (11) 1  
(10%) 
3  
(27%) 
9  
(81%) 
0 4 
(36%) 
2 
(18%) 
9  
(81%) 
3D (23) 6  
(26%) 
5  
(22%) 
3  
(13%) 
5  
(22%) 
13 
(57%) 
8 
(35%) 
21  
(91%) 
Total 
(507) 
43  
(8%) 
40  
(8%) 
54  
(11%) 
111  
(22%) 
144 
(28%) 
132 
(26%) 
254 
(50%) 
 
* Includes both endovascular and surgical revascularisation 
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Figure 2.1 Ulcer depth and major adverse clinical events 
 
 
*p <0.001 
 
Figure 2.2 Ulcer stage and major adverse clinical events 
 
 
*p <0.001 
 
There were 144 hospital admissions with sepsis during the follow-up period (the median 
duration of hospital admission 14 days IQR 6 to 60 days). There were no significant 
differences between the depth and stage of the ulcer at presentation and a requirement for 
drainage of sepsis. Increasing ulcer depth and stage were independently associated with 
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more frequent hospital admissions for sepsis  (Figures 2.3 and 2.4) and a greater duration 
of inpatient stay  (Tables 2.3 and 2.4). 
 
Figure 2.3 Septic admissions and management by ulcer depth (p>0.05) 
 
 
 
Figure 2.4 Septic admissions and management by ulcer stage (p>0.05) 
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Table 2.3: Inpatient stay by ulcer grade 
 
 
 
Number of Limbs Mean Inpatient Stay 
(Days) 
Grade A 
 
229 3.9 
Grade B 
 
74 9 
Grade C 
 
147 5.6 
Grade D 
 
54 15.2 
 
 
Table 2.4: Inpatient stay by ulcer depth 
 
 
 
Number of Limbs Mean Inpatient Stay 
(Days) 
Depth 0 
 
63 2.3 
Depth 1 
 
366 5.4 
Depth 2 
 
21 13.4 
Depth 3 
 
54 15.1 
 
 
The mean time to ulcer resolution was 4 months (range 1 to 63 months) – in 61 (12%) 
cases there was persistent ulceration despite intervention at the end of the study period. 
 
The development of recurrent ulceration was associated with a significantly greater risk of 
subsequent major adverse event, even if the first presentation had been with superficial 
ulceration, without infection or ischaemia being present [UoT 0A and 1A] (Figure 2.5).  
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Figure 2.5: Recurrent ulceration on subsequent major adverse clinical events (p<0.005) 
 
  
 
A diagnosis of ischaemia (as defined by the presence or absence of a palpable foot pulse) 
was associated with a significant reduction in survival (p <0.005) (Figure 2.6). The depth 
of ulceration and presence/absence of sepsis were also examined using Kaplan-Meier 
methodology – neither had an effect on survival (these data are not shown). 
 
Figure 2.6: Survival with and without the presence of ischaemia  
 
Time (days) 0 365 730 1095 1460 1825 2190 
PAOD  (At risk/Events) 153/0 109/28 70/39 39/49 26/51 4/54 2/55 
No PAOD (At risk/Events) 225/0 186/14 137/25 94/32 52/39 17/43 1/44 
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2.4 Chapter summary 
 
These data demonstrate the burden placed on hospital services by the complications of 
DFU. These data support existing evidence that a structured approach to the assessment of 
all DFU should include assessment for sepsis and ischaemia and that these features when 
taken together with the depth of the ulcer at first presentation can identify patients at 
highest risk of subsequent major adverse events. It also appears from the presented data 
that even for patients who may appear to present at the benign end of the DFU risk 
spectrum, a recurrent ulcer indicates a significantly poorer prognosis. This merits further 
investigation.  
 
A retrospective review of this type will have a number of limitations. A potential 
confounding issue is the proportion of patients with DFU who may have been lost to 
follow-up. However given the nature of this patient population and the effectiveness of 
local electronic health records with the CHI number, it seems unlikely that this would 
meaningfully influence the presented data. We are unable to make any meaningful 
comment on the number of patients with septic complications managed in the community.  
Furthermore we did not attempt to make a comment on the effectiveness of arterial 
reconstruction in this patient cohort given the small number of patients who underwent 
such procedures. 
 
The impact of vascular intervention on an ischaemic limb may be judged by amputation-
free survival, graft or vessel patency rates and haemodynamic measures. Defining success 
following intervention for DFU is more complicated. Given the heterogeneous nature of 
much of the published work on DFU, the adoption of a standardised clinical assessment is 
fundamental to allow meaningful systematic review and meta-analysis [Chan 2015]. UoT 
would seem to be appropriate for this.  
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Chapter 3 – Patient selection, demographics and the process of skin biopsy 
 
This chapter summarises the process of patient selection (including the ethical approvals 
that were sought to allow completion) and describes the demographics of the patient 
groups from which skin biopsies were obtained for the experiments described in chapters 4 
and 5.  
 
3.1 Ethical approval and patient selection 
 
Ethical approval to recruit patients to this study was obtained from the West of Scotland 
Research Ethics Committee (WoSRES) (Research Ethics Committee reference number 
13/WS/0008).  
 
A second ethic application was made to the Glasgow Caledonian Skin Tissue Bank to 
access additional skin samples (this second ethical approval was sought to access skin from 
the foot). 
 
Patients were considered eligible for inclusion if they presented with critical limb 
ischaemia as a consequence of peripheral arterial occlusive disease (with or without a 
concurrent diagnosis of DM) and had been admitted for lower limb arterial reconstruction 
in the form of infra-inguinal bypass, or major limb amputation and were able to provide 
informed consent. The clinical decision-making to proceed with intervention was 
performed according to the symptom pattern reported by the patient, clinical assessment 
and with the results of cross-sectional angiography (either CTA or MRA).  Both elective 
and non-elective patients were considered to be eligible for inclusion. The only exclusion 
criterion was cognitive dysfunction that would limit ability to obtain fully informed 
consent. 
 
Patients undergoing elective orthopaedic foot surgery for mechanical deformity were 
recruited as a control group (the presence of peripheral arterial occlusive disease was 
excluded by a combination of clinical history, examination and ABPI assessment – no 
arterial imaging was performed on this group). 
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All patients were approached pre-operatively and the study explained. A patient 
information sheet was provided (the patient information sheet varied depending on the 
patient group). Fully informed consent was obtained and a consent form signed.  
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3.2 Methods 
 
Patients were recruited to the study from February 2013 until May 2014.Local and national 
(PACS) electronic patient record systems were scrutinized through case-linkage using the 
Community Health Index (CHI) number to complete the basic demographic dataset [Stuart 
2013]. A standardised data set was defined which included basic demographic data (age, 
sex, smoking status). All patients had been screened for DM (a local standard of care in the 
investigation of patients with symptomatic PAOD). Pharmacological therapy was recorded 
(statin, antiplatelet and oral hypoglycaemic medication/insulin).  
 
The type of radiological imaging for arterial assessment was documented and the pattern of 
PAOD recorded. The CHI number was used for this purpose to access nationally archived 
radiological data. 
 
The presence of sepsis was documented using previously described and validated criteria 
[Lavery 2007]. Pre-operative therapeutic and prophylactic antibiotic therapy was recorded. 
 
Haemodynamic assessment (ABPI/TBI) was performed in accordance with guidelines 
published by the Society for Vascular Technology [Cole 2001]. In patients that had 
previously undergone minor amputation toe pressures were recorded from the most medial 
remaining digit. 
 
The type of surgical procedure was documented, as was the outcome with specific 
reference to wound healing.  
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3.3 Summary of patient demographic data 
 
In total 45 patients were recruited through a combination of the ethical approvals. There 
were 18 patients with DM and PAOD, 22 patients with PAOD and 5 patients in the control 
group. The patient dataset is summarised by group in Table 3.1. 
 
The basic demographic data of the different patient groups was broadly as may have been 
anticipated. There was a male preponderance and smoking was common in the patients 
with PAOD. None of the orthopaedic control patients had a diagnosis of DM. Of the cohort 
with DM and PAOD all had Type II DM. Ten of these patients were managed with insulin 
and the remaining patients were on oral hypoglycaemic medication.  
 
There were 3 patients with soft tissue infection at the time of the primary procedure. In 
each case Staphylococcus aureus was cultured from wound swabs taken from sites of 
DFU. All three were prescribed antibiotic therapy (regimes included Tazocin n=1, 
Vancomycin and Metronidazole n=1 and Benzylpenicillin, Flucloxacillin and 
Metronidzole n=1).  
 
Patients not receiving pre-operative therapeutic antibiotic therapy were prescribed 
antibiotic prophylaxis according to local protocol. The vascular surgical patients were 
prescribed Flucloxacillin and Gentamicin for arterial reconstruction and Flucloxacillin and 
Metronidazole for major limb amputation. In patients with a Penicillin allergy the 
Flucloxacillin was substituted for Teicoplanin. The orthopaedic patients received 
Cefuroxime. 
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Table 3.1 Summary of patient demographic data 
 
 
 
Control Group 
(n=5) 
PAOD (with DM) 
(n=18) 
PAOD (without DM) 
(n=22) 
Presentation 
Arterial Rest Pain 
Ulceration/Tissue Loss 
Mechanical Deformity 
 
0 
0 
5 
 
4 (22%) 
14 (78%) 
0 
 
11 (50%) 
11 (50%) 
0 
Mean age (range) 50 years (27-71 years) 64 years (51-83 years) 64 years (39-86 years) 
Sex (Male) 1 (20%) 13 (72%) 15 (66%) 
Pharmacotherapy 
Antiplatelet Agent 
Statin 
 
1 (20%) 
1 (20%) 
 
16 (89%) 
16 (89%) 
 
21 (95%) 
17 (77%) 
Smoking Status 
Non-smoker 
Former-smoker 
Current smoker 
 
5 (100%) 
0 
0 
 
3 (17%) 
4 (22%) 
11 (61%) 
 
2 (9%) 
7 (32%) 
13 (59%) 
Mean Absolute Ankle 
Pressure (range)  
Mean Absolute Toe 
Pressure (range) 
120mmHg  
(110-130mmHg) 
80mmHg 
(70-90mmHg) 
56mmHg 
(30-120mmHg) 
40mmHg 
(28-68mmHg) 
59mmHg 
(30-138mmHg) 
42mmHg 
(30-70mmHg) 
ABPI 
Normal range (0.9-1.3) 
Occlusive Disease (0.3-0.8) 
CLI (<0.3) 
Incompressible (> 1.3) 
 
5 (100%) 
0 
0 
0 
 
2 (11%) 
4 (22%) 
5 (28%) 
7 (39%) 
 
0 
16 (73%) 
5 (23%) 
1 (4%) 
Foot Sepsis  0 3 (17%) 0 
Arterial Imaging 
CTA 
MRA 
DSA 
 
N/A 
N/A 
N/A 
 
6 (33%) 
11 (61%) 
1 (4%) 
 
8 (36%) 
14 (64%) 
0 
Pattern of Arterial Disease 
Aorto-iliac 
Femoral bifurcation 
Femoro-popliteal  
Femoro-popliteal/crural 
Crural disease in isolation 
 
N/A 
N/A 
N/A 
N/A 
N/A 
 
0 
1 (6%) 
0 
11 (61%)  
6 (33%) 
 
0 
0 
11 (50%) 
11 (50%) 
0 
Procedure 
Major Limb Amputation 
Infra-inguinal Bypass 
Forefoot Reconstruction 
 
0 
0 
5 
 
11 (61%) 
7 (39%) 
0 
 
10 (45%) 
12 (55%) 
0 
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The mean absolute pressures (ankle and digital) are summarised in Table 3.2. MRA was 
the preferred method of arterial imaging. 
 
Table 3.2 Description of absolute ankle and digital pressure with reference to the clinical 
presentation 
 
 
 
PAOD (with DM) 
 
PAOD (without DM) 
 
Rest pain (absolute pressures) 
• Ankle (range) 
• Toe (range) 
 
45mmHg (32-54mmHg) 
42mmHg (28-52 mmHg) 
 
54mmHg (30-82mmHg) 
44mmHg (30-71mmHg) 
Tissue loss 
• Ankle (range) 
• Toe (range) 
 
60mmHg (30-120mmHg) 
40 (30-68mmHg) 
 
72mmHg (60-130mmHg) 
53mmHg (30-60) 
 
 
There was one wound failure following major limb amputation in a patient with DM and 
PAOD necessitating revision to a higher level (transtibial to transfemoral). Of the patients 
managed with infra-inguinal bypass there was one graft and subsequent wound failure. 
This patient went on to have a major limb amputation performed. There were no wound 
failures in the patients with PAOD following surgical intervention on the index admission. 
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3.4 Process of skin biopsy 
 
Full thickness skin biopsies were taken using a scalpel blade (maximal dimensions 10mm 
by 5mm) at the beginning of each surgical procedure (all of the skin biopsies were taken 
by the author). Specimens were harvested from the most proximal and distal incision sites, 
which was determined by the proposed surgical procedure being performed – for infra-
inguinal bypass skin was biopsied from the groin and leg incisions, for major limb 
amputation skin was biopsied from the foot and then either the leg (transtibial amputation) 
or thigh (transfemoral amputation) and for the control group skin biopsies were performed 
from the forefoot (at the level of the 1st metatarsophalangeal joint). Given that ulceration is 
associated with changes in Cx expression [Wang 2007, Wright 2009, Chin 2011] skin 
biopsies were taken from anatomical sites distinct from acute/chronic ulceration.  
 
Following this the skin samples were immediately placed in a universal container with 5ml 
of complete Dulbecco’s Modified Eagle Medium (cDMEM)	 (Lonza, Wokingham, UK) 
with 0.5 mg/mL Puromycin (Sigma-Aldrich, Gillingham, UK) and 50ml of Foetal Bovine 
Serum (FBS), which had been refrigerated at 4oC. Following this the sample was placed in 
ice and transferred immediately to the laboratory.  
 
Subsequent tissue handling was then defined by experiment (the methodologies are 
described in chapters 4 and 5 respectively). 
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3.5 Chapter summary 
 
The demographic data described are broadly as would have been expected. The patients 
with DM/PAOD and PAOD in isolation are comparable in terms of age, sex and smoking 
status. It is reassuring to see that cardiovascular risk had been considered and addressed 
appropriately with the administration of an antiplatelet agent and statin for the majority of 
the patients with PAOD. The control group differs reflecting an entirely different patient 
demographic from the cohort with arterial disease. No adjustment could be made for this. 
 
The absolute pressures derived at both the ankle and toe, are surprisingly high when 
compared with validated standards in the world literature [European Working Group on 
Critical Limb Ischaemia 1992]. It seems likely that there has been consistent 
methodological error, which has skewed these data.  
 
The patterns of PAOD are as would be expected – patients with DM have a higher burden 
of more distal arterial disease, with one third of patients having crural vessel occlusive 
disease in isolation. The pattern of intervention would also seem to reflect this with more 
of the patients with DM being managed with major limb amputation. 
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Chapter 4 - Basic Histology and Immunohistochemistry 
 
4.1 Introduction 
 
As has been previously discussed Cx43 is broadly expressed and can be found in all 
epithelial layers of ectodermal origin [Richards 2005], with more focal distribution in the 
basal keratinocytes (stratum basale) and with the suprabasal cells (stratum spinosum) 
demonstrating higher expression [Richard 2000, Brandner 2004]. Cx43(Ser368) has been 
identified in healthy skin (and noted to be up-regulated in response to injury) [Richards 
2004]. In the cardiac myocyte the expression of Cx43 would appear to be down regulated, 
in response to prolonged hypoxia (more than 5-hours) [Zeevi-Levin 2005], where-as 
Cx43(Ser368) seems to be rapidly up regulated [Johansen 2011]. 
 
In this chapter the expression of Cx43 and Cx43(Ser368) in skin biopsies is explored in 
vivo, for patients with PAOD with and without DM, as well as from the previously defined 
control group. Effectively we assess whether there are reproducible changes in either the 
expression of Cx43 and Cx43(Ser368) such that they could have utility as biological 
markers of ischaemia in patients presenting with occlusive arterial disease of the lower 
limb and DFU. 
 
Specific aims were to 
 
i. To explore the presence of Cx43 and compare expression between proximal and 
distal skin biopsy sites in patients with and without DM undergoing vascular 
surgical intervention with comparison with a control group without DM or PAOD 
 
ii. To assess whether Cx43(Ser368) could be identified in the same skin biopsies 
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4.2 Patients and Methods 
 
The process of patient selection and skin biopsy has been summarised in the previous 
chapter. For these experiments three samples were obtained from each patient group 
(PAOD with and without DM and control). 
 
4.2.1 Tissue Fixation 
 
On arrival in the laboratory the skin biopsies were removed from the cDMEM and rinsed 
with Phosphate Buffered Saline (PBS), prior to fixation. The cryobar of the cryostat was 
activated, cooling to approximately minus 50oC. Mounting discs had OCT placed centrally 
and were cooled until the OCT was opalescent, following which the tissue sections were 
mounted. OCT was then placed over the tissue and the disc returned to the cryobar for 5 
minutes.  When the OCT had set the tissue was sectioned (tissue sectioning was performed 
at 5 microns).  Sectioned tissue was mounted on Colourcoat Adhesion; Silane Coated 
microscope slides (Cellpath). Each slide had 12 tissue sections mounted from each skin 
biopsy. On completion slides were placed in a slide box and stored at minus 80oC until 
ready for processing. 
 
4.2.2 Haematoxylin and Eosin Staining 
 
Slides were allowed to warm to room temperature for ten minutes prior to performing 
basic histology with Haematoxylin and Eosin staining. This process was performed using a 
series of Coplin jars. Slides were first placed in Ehrlich’s Haematoxylin for fifteen 
minutes, following which they were transferred to a Coplin jar containing ‘Scott’s tap 
water substitute’. After five minutes the slides were rinsed under running water, prior to 
being placed in another Coplin jar, containing 1% Eosin for a further five minutes. The 
excess Eosin was blotted from the slide, which was then rinsed under running tap water for 
a further 5 minutes. Slides were then dipped in acid/alcohol, following which the tissue 
section was covered with DPX and a glass cover slip. Microscopy was performed and 
images collected at x10, x20 and x40.  
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4.2.3 Immunohistochemistry 
 
This technique allows identification of tissue constituents through highly specific 
antigen/antibody interactions. Two antibodies are required: the primary antibody, which 
recognised the antigen under investigation and a secondary antibody, conjugated to a 
chemical (fluorochrome) that fluoresces at a specific wavelength. The procedure was 
performed in accordance with the standard laboratory protocol (including antibody 
concentration), the methodology of which is summarised. 
 
Slides were removed from the minus 80oC freezer and placed in ice cold 100% methanol in 
a Coplin jar to fix the sections on the slides for 10 minutes. Following this the slides were 
washed with PBS (pH 7.4) to rehydrate the tissue sections. PBS containing 0.1% Titron 
(Sigma-Aldrich Triton®X-100) was then used to permeabilise the cells (to facilitate entry 
of the antibodies). Given the viscosity of this solution, it was mixed using a magnetic 
stirrer. This was left on the slides for thirty minutes. Following this a solution of PBS-T 
containing 5% milk (Marvel original dried skimmed milk) was placed on the slides for 
thirty minutes to block any non-specific antibody binding. 
 
Primary antibodies were prepared to a volume of 100µl in diluted in 5% milk-PBS - mouse 
anti-Cx43 (Sigma-Aldrich, St Louis, USA), rabbit anti-Cx43(Ser368) (Abcam, Cambridge, 
UK) and Loricin (Abcam, Cambridge, UK) were prepared at 1:500,1:100 and 1:400 
respectively. Slides were incubated at 37°C for one hour in a humidity box in darkness. 
The cells were washed in PBS every 20 minutes for 45 minutes within the humidity box. 
The secondary antibodies were diluted in 5% milk-PBS - Secondary anti-mouse and -
rabbit antibodies conjugated to either AlexaFluor 488 or AlexaFluor 594 (1:500; 
Invitrogen, Paisley, UK) with incubation in the dark for 45 minutes at 37°C in a humidity 
box. The cells were washed overnight at 4°C in PBS in a humidity box and darkness. The 
PBS was changed at least twice before putting the plate on a rocker overnight at 4°C. The 
nuclei were all stained by a subsequent incubation with 4'-6-Diamidino-2-phenylindole 
(DAPI), a nuclear counterstain (1:1000 in 5% milk-PBS).  Finally, the excess PBS was 
removed from the coverslips by dipping in distilled water and the slides were mounted 
using Fluorsave (Calbiochem, Nottingham, UK)  
 
Immuno-labelled tissue sections were viewed under a x40 oil-immersion lens mounted on 
a Zeiss 200 Axioscope microscope linked up to a Zeiss LSM 510 META laser scanning 
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system, using the following settings: Alexa 488 was excited using the Argon laser at 488 
nm excitation and emission at 500-550 nm. Alexa 594 was excited with a Helium Neon 
laser at 543 nm excitation and emission at 600-650 nm.  
 
Images of adequate quality were captured and processed using Adobe photoshop software 
allowing the creation of an overlay. Following this the images were saved and stored 
electronically as JPEG files. Analysis is qualitative. 
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4.3 Results 
 
Skin biopsies were taken from 14 patients for basic histology and immunohistochemistry. 
A summary of the patients is described in Table 4.1. 
 
Table 4.1 Summary of patient demographic data  
 
 
 
Control Group 
(n=3) 
PAOD (with DM) 
(n=5) 
PAOD (without DM) 
(n=6) 
Presentation 
Arterial Rest Pain 
Ulceration/Tissue Loss 
Mechanical Deformity 
 
0 
0 
3 
 
0 
5 
0 
 
2 
4 
0 
Mean age (range) 49 years (27-71 years) 64 years (57-78 
years) 
59 years (39-80 years) 
Sex (male) 1 4 4 
Mean Ankle/Toe Pressure 115mmHg/74mmHg 48mmHg/40mmHg 58mmHg/45mmHg 
Foot sepsis 0 1 1 
Pattern of Arterial Disease 
Aorto-iliac 
Femoral bifurcation 
Femoro-popliteal 
Femoro-popliteal/Crural 
Crural 
 
N/A 
N/A 
N/A 
N/A 
N/A 
 
0 
0 
0 
3 
2 
 
0 
0 
4 
2 
0 
Procedure 
Major Limb Amputation 
Infra-inguinal Bypass 
Complex Forefoot 
Reconstruction 
 
0 
0 
3 
 
3 
2 
0 
 
3 
3 
0 
 
No meaningful immunohistochemistry could be defined from 1 of the control samples. In 5 
samples from the PAOD (with and without DM) there was only adequate quality data from 
either proximal or distal biopsies. There were 6 skin biopsies (PAOD with DM n=3; 
PAOD n=3) that had good quality proximal and distal biopsy sections available (in 5 of 
these cases the distal biopsy was taken from the foot). 
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4.3.1 Basic histology from skin biopsy of the leg and foot 
 
Basic histology demonstrated a standard architectural appearance and confirmed that the 
sectioning had been perpendicular to the skin surface such that meaningful comment could 
be made with regard to the immunohistochemistry. An example is provided in Figure 4.1. 
For cases where sectioning had been inadequate samples were discarded.  
 
Figure 4.1 Haematoxylin and Eosin Staining (x10) of a diabetic patient managed with a 
major limb amputation, with skin biopsies taken proximally (level of the tibial plateau) and 
distally (level of the 1st metatarsophalangeal joint) 
 
Proximal skin biopsy                             Distal skin biopsy 
	 	
 
The proximal skin sample demonstrates thin skin – the stratum lucidum (which is only 
present in very thick skin and would appear as a homogenous layer between the stratum 
granulosum and the keratinized layer) is absent. The interrupted white line indicates the 
stratum basale – the germinal layer of the epidermis. The interrupted black line indicates 
the stratum granulosum, a layer that is characterized by intracellular granules, which 
contribute to the process of keratinization. Between these layers is the stratum spinosum 
that contains cells that are in a process of growth and which are beginning to synthesise 
keratin. Above these layers is the stratum corneum, which consists of flattened, fused cell 
remnants that are principally composed of keratin. 
 
The basic skin architecture appeared to be preserved in all samples. The only difference 
identified (as demonstrated in Figure 4.1) was with regard to the type of skin (thin 
skin/thick skin). 
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4.3.2 Immunohistochemistry from skin biopsy of the leg      
 
The distribution of Cx43 was comparable when biopsies had been taken from thin skin 
(Figure 4.2). Cx43 was expressed primarily in the stratum spinosum. 
 
Figure 4.2: Immunohistochemistry for Cx43 (x40) with skin biopsies taken from a 
diabetic patient undergoing femoro-popliteal bypass. The proximal biopsy was taken from 
the groin and the distal biopsy was taken from the medial leg. An overlay has been 
performed. Cx43 is stained green and DAPI nuclear staining (blue) is included. 
 
Proximal skin biopsy                       Distal skin biopsy 
	  	
 
The spatial distribution of the Cx43 staining demonstrated in this example was consistent 
with the results from all of the other sections, with Cx43 most abundant in the stratum 
spinosum. The spatial distribution and expression of Cx43 was similar in the proximal and 
distal skin biopsies of patients having femoro-popliteal bypass performed. All staining for 
Cx43(Ser368) from skin biopsies of the thigh or leg was negative – these data have not 
been shown. Similarly there was no expression of Cx43(Ser368) in the proximal skin 
biopsies of patients having major limb amputation performed.  
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4.3.3 Immunohistochemistry from skin biopsy of the foot 
 
The immunohistochemistry of the skin biopsies taken from the feet of patients generated a 
different qualitative result pattern, which is summarised in the matrix on the following 
page (Figure 4.3).  
 
In the patients with PAOD (with or without DM) the ankle and toe pressures were less than 
60mmHg and 50mmHg respectively. Cx43 expression and spatial distribution appeared to 
be consistent with skin biopsies from the thigh/leg and did not appear to be down-regulated 
in response to ischaemia (irrespective of DM status). Cx43(Ser368) was positively 
identified with a pattern of expression similar to Cx43 (irrespective of DM status).  
 
In the control group mean ankle and toe pressures were 115mmHg and 74mmHg 
respectively. Cx43 expression and spatial distribution was consistent with skin biopsies 
from the thigh/leg (and the ischaemic feet). Cx43(Ser368) was not identified in any of the 
control samples. 
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Figure 4.3: Matrix summarizing the expression of Cx43 and Cx43(Ser368) in skin 
biopsies from the foot (x40). In these examples Loricrin (a terminally differentiating 
structural protein found above the granular layer in the epidermis) has also been stained for 
and a recognised pattern of protein expression identified. 
 
Normal Foot	 
Loricrin                           Connexin 43                  Connexin 43(Ser368) 
				 				 	
Diabetic Ischaemic Foot 
				 				 	
Ischaemic Foot 
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Chapter summary 
 
A standard architectural skin structure has been demonstrated using basic histology. The 
spatial distribution of Cx43 in human skin is consistent with previously published data, 
with Cx43 expressed predominantly in the stratum spinosum and with more focal staining 
in the stratum basale. The presence of significant ischaemia of the foot does not appear to 
significantly influence Cx43 expression. Cx43(Ser368) was not identified in any of the 
proximal skin sections nor in the skin sections taken from the feet of the control 
population. There was marked Cx43(Ser368) expression identified in the sections taken 
from ischaemic feet. The spatial distribution of the protein in the stratum spinosum is 
broadly as would be expected from previously published data. 
 
A fundamental conceptual error with the primary study design became apparent following 
early recruitment of patients having femoro-popliteal bypass performed. As has been 
described the Cx43 expression was consistent and Cx43(Ser368) was not demonstrated. As 
has been described discussed, CLI as a consequence of PAOD is primarily a disease of the 
skin. Therefore it would seem most appropriate to investigate skin of the foot. During the 
study period there were no patients managed with popliteal to pedal artery bypass recruited 
to the study. As such all of the biopsies taken from the feet (with the exception of the 
control group) were from patients undergoing major limb amputation.  
 
Although the quality of the tissue sectioning was good, some samples were discarded 
because of poor sectioning technique. There were a series of failures of the 
immunohistochemistry. In some cases tissue samples became dissociated from the slides 
during the preparation stage. There were some slides where there was inadequate staining 
of the tissue section, which was presumably a consequence of an unrecognized 
methodological error. This was addressed by the recruitment of additional patients, such 
that the dataset could be completed adequately.  
 
Previous researchers have demonstrated Cx43(Ser368) in human skin [Richards 2004]. 
The absence of Cx43(Ser368) in these sections may have been a consequence of relatively 
low Cx43(Ser368) expression. Another possibility is technical error with the use of an 
antibody concentration that was too low. However if this were the case it would suggest 
that the changes identified in the sections taken from the ischaemic feet are more 
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significant, with what would therefore appear to be substantial up regulation of 
Cx43(Ser368).  
 
In two of the study group patients there were wound failures following surgical 
intervention (failure of amputation n=1, failure of lower limb bypass n=1). Unfortunately 
the skin biopsies from these patients were used for cell culture, rather than for 
immunohistochemistry. Given the subsequent clinical course it would have been 
interesting to explore the proximal skin biopsy for the amputation patient and the distal 
skin biopsy for the patient who had lower limb bypass performed for Cx43(Ser368). 
 
Cx43 expression was consistent in all of the skin biopsies in terms of qualitative 
expression and spatial distribution. Consequently it would seem that this protein has no 
clinical utility as a biomarker for ischaemia in patients with PAOD. The apparent up 
regulation in ischaemic skin of Cx43(Ser368) is a novel finding. Given that Cx43(Ser368) 
could not be identified in any of the other skin samples there is an implication that a 
significant up regulation of protein expression is being seen. As there is consistency 
between patients with and without DM it seems reasonable to assert from these data that 
Cx43(Ser368) protein may have utility as a biomarker of ischaemia. Finally these changes 
would appear to support the assertion that the skin of the foot may be the best place to 
identify a biomarker for ischaemia. 
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Chapter 5 – Connexin 43 and Connexin 43(Ser368) expression in-vitro from human 
keratinocytes and fibroblasts 
 
5.1 Introduction 
 
In this chapter the in-vivo findings described in chapter 4 are further explored with specific 
reference to the protein expression of Cx43 and Cx43(Ser368) using human keratinocytes 
and fibroblasts derived from the skin biopsies. As well as examining protein expression 
following exposure to a hypoxic environment, the potential effects of effect of glycaemia 
and infection are also explored.  
 
Specific aims were to 
 
i. To investigate the expression of Cx43 and Cx43(Ser368) protein in keratinocytes 
and fibroblasts in response to a hypoxic challenge 
 
ii. To explore whether Cx43 and Cx43(Ser368) protein expression is influenced by 
different glycaemic environments 
 
iii. To investigate whether Cx43(Ser368) protein expression is influenced by an 
infection (in laboratory conditions)  
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5.2 Patients and methods 
 
The process of patient selection and skin biopsy has been summarised in the previous 
chapter. For each experiment three samples from each patient group (PAOD with and 
without DM and control) was considered to be appropriate. The methodologies described 
below have been validated internally. 
 
5.2.1 Isolation of human fibroblasts and keratinocytes from skin biopsy  
 
Tissue sections were transported to the laboratory where cDMEM was removed from the 
universal container. The tissue samples were washed in 0.2% Chlorhexidine for 5 minutes. 
The Chlorhexidine was then discarded and the process repeated. After a further 5 minutes 
the Chlorhexidine was again discarded and the tissue sample washed with 
Gentamicin/Amphotericin solution for 5 minutes. This step was then repeated. Using a 
sterile size-10 blade, excess subcutaneous tissue was excised and disposed of. Following 
this the tissue was cut into thin strips. Following this the antibiotic solution was discarded 
and the tissue sections placed in dispase (0.5% w/v in Ca2+/Mg2+ free PBS) overnight at 
4oC. The following day the epidermis and dermis were split using forceps and a scalpel 
blade.  
 
Fibroblast culture 
 
The following day, using sterile forceps the epidermis was peeled from the dermis. The 
dermis was then cut into small sections using a size-10 blade. These dermal explants were 
then placed in a T25 Corning flask using sterile forceps. Care was taken to ensure that the 
explants were widely spaced. At this stage 2ml of cDMEM was added to the flask, which 
was then placed in an incubator (37oC with 5% CO2). The dermal explants were allowed to 
settle for 48 hours following which the media was removed and the explants washed with 
Ca2+/Mg2+ free PBS to remove any debris/non-viable cells. A further 3ml of cDMEM was 
then added to the flask. The process was repeated on alternate days until a confluent 
monolayer of fibroblasts had grown. 
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Keratinocyte culture 
 
The epidermis was then finely chopped until ‘slurry’ was formed. This was then 
transferred to the bottom of a universal container with the flat side of the scalpel and 2-3 
ml of trypsin added. The solution was left to stand for 2-3 minutes, following which it was 
agitated with a pipette to create a cell suspension. At this stage 10 ml of EpilifeTM (Epilife 
medium with 1% Epilife-defined growth supplement (formulation proprietary), 10 mg/mL 
genatamicin, and 0.25 mg/mL amphotericin B [Cascade Biologics, Invitrogen, Paisley, 
UK]) with 10% chelexed serum was added to the epidermal suspension. A cell strainer was 
then placed over a fresh universal container and the suspension transferred by pipette. This 
was then spun down in the centrifuge for 5 minutes at 400 rpm. When this had been done 
the supernatant was removed by Pipette with care taken not to disturb the cellular pellet 
and 2ml of EpilifeTM with 10% chelexed serum was added to re-suspend the cells. This 
new suspension was then transferred to T25 flasks that had been prepared with a coating 
matrix (1ml of the cell suspension was added to each flask) and made up to 5ml with 
Epilife with 10% chelexed serum. On the second day the media was changed and from that 
point EpilifeTM was used (without chelexed serum). Media was changed on alternate days 
until the cells became confluent at which time they were split. 
 
All surplus human tissue was discarded in accordance with laboratory protocol. 
 
5.2.2 Splitting cells 
 
Cells were split from either the dermal explants or from flasks when they had grown to 
either 80% confluence or greater. Media was removed and the cells washed twice with 
PBS to remove any non-viable cells. Trypsin was then added to the flask (1ml to the 
dermal explants in T25 flasks and 2ml to the cells in T75 flasks). The flasks containing the 
Trypsin were then returned to the incubator for three minutes, following which either 5ml 
of EpilifeTM or cDMEM were added (for keratinocytes and fibroblasts respectively). The 
cells were placed in a Universal container and then placed in the centrifuge for 5 minutes 
at 10,000g. The supernatant was discarded, the pellet re-suspended and the cells re-plated 
(to expand the cell colonies cells were re-plated in T75 flasks). 
  
 
 
 
 
 74 
5.2.3 Freezing Cells 
 
Keratinocytes and fibroblasts were harvested on the second passage after they had grown 
to confluence in T75 flasks. Trypsin was added to the flask (2ml), which was then replaced 
in the incubator for three minutes, following which 5ml EpilifeTM (keratinocytes) or 
cDMEM (fibroblasts) was added. The solution was removed from the flask and added to a 
Universal container for centrifugation (5 minutes at 10,000g). The supernatant was 
discarded and the pellet re-suspended in freezing serum prior to transfer to a cryovial. The 
cells were then slowly frozen to minus 70oC and thereafter stored in liquid nitrogen. 
  
5.2.4 Cell Challenges 
 
A variety of different cell challenges were experimented with. In each case cells were 
grown to approximately 80% confluence in 6-well plates prior to challenge. Cells were 
used on the second or third passage. 
 
5.2.4.1 Hypoxia 
 
Cells were challenged in a Hypoxia Chamber (StemcellTM Technologies). The chamber 
was prepared in accordance with the manufacturer’s instructions for use. Plates of cells 
were placed in the chamber along with a petridish containing 20ml of distilled water, 
following which the chamber was closed. Gas was then allowed to flow into the chamber 
at 25l/minute for 4 minutes in accordance with the manufacturers instructions for use, 
following which the chamber was sealed. Cells were challenged in a 1% Oxygen/5% 
Carbon Dioxide/Nitrogen environment. Fibroblasts were challenged in this environment 
12, 24 and 48 hours. Keratinocytes were challenged for 6, 12 and 24 hours (cell death was 
seen with the keratinocytes if they were left in these conditions for 48 hours).  
 
5.2.4.2 Peptidoglycan 
 
Peptidoglycan (PGN) is a polymer that is found outside the plasma membrane of most 
bacteria, forming a substantially thicker layer in gram-positive bacteria. In these 
experiments challenge with PGN was designed to mimic a Staphylococcal infective insult 
– gram-positive aerobic bacteria are the most common organisms isolated from DFU 
[Lipsky 1990, Tentolouris 1999]. 
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Prior to challenge with PGN cells were treated for 60 minutes with culture media without 
antibiotics. PGN was then added at 10µl/ml. Cells were harvested at 0, 6 and 24 hours 
following the challenge. 
 
5.2.4.3 High and Low Glucose Conditions 
 
To prepare media for high and low glucose conditions, a 1% stock of Bovine Serum 
Albumin (BSA) was first made in both low glucose and high glucose, warmed serum free 
DMEM (sfDMEM). This was then filter sterilised. Using this BSA stock 100ml of low and 
high glucose DMEM with 0.1% BSA was prepared. 
 
A 10µM insulin stock was prepared by adding 58.8µl to 9.9412ml of low glucose 
sfDMEM with 0.1% BSA. Low and high insulin glucose media (10mls) was then prepared 
as described in the following tables. 
 
Table 5.1 Preparation of high and low glucose media 
 
Metabolic 
Conditions 
Glucose 
Concentration 
(mM) 
Insulin 
Concentration 
(nM) 
sfDMEM + 0.1% 
BSA (ml) 
Insulin Stock (µl) 
Low Glucose 5.5 1 9.999 1 
High Glucose 25 10 9.633 10 
 
Cells were maintained in standard conditions in 6-well plates until ready for 
experimentation. Cells were treated for five days in either high or low glucose 
environments. The cells were washed daily with PBS and the media was changed. 
 
5.2.5 Protein Harvest 
 
Cells were cultured in 6-well plates for protein extraction and then challenged as required. 
After treatment the media was removed (the supernatant was collected in eppendorf tubes 
and frozen at minus 20oC), following which the samples were washed twice with PBS. The 
cells were then lysed using 100µl of ice-cold lysis buffer and harvested by scraping using 
the rubber plunger of an insulin syringe. The cell lysates were then added to ice-cold 
eppendorf tubes and sonicated three times at 15MHz for ten seconds. Samples were frozen 
at minus 70oC until required. 
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Previous local data and previously published data suggested that 20mcg of protein should 
be adequate for Cx43 staining. Work from previous authors suggested that a similar 
protein concentration should allow adequate staining of Cx43(Ser368). 
 
5.2.6 Bradford Protein Assay 
 
The Bradford protein assay, a spectroscopic analytical procedure based on the Lowry 
assay, which measures the reaction of proteins with alkaline copper tartarate and Folin 
reagent was used to determine the protein concentration from each sample. The BioRad 
system (BioRad, UK) was utilised.  
 
In summary, 5µl of each protein sample was added in duplicate to a 96-well plate. This 
was then mixed with 25µl of Reagent A + S (1ml of Reagent A and 20µl Reagent S) 
following which 200µl of Reagent B was added. Samples were then incubated at room 
temperature on a plate rocker for 15 minutes to allow colour to develop. Following this a 
plate reader was used to calculate absorbance. Protein concentration was then calculated 
using a linear regression model generated using a known concentration solution of BSA (0 
to 1mg/ml) prepared in the same buffer used for protein extraction and Microsoft Excel. 
 
5.2.7 Western Blot Analysis 
 
Western Blot analysis was completed using pre-cast NuPAGER Bis-Tris mini gels  (Novex 
by life technologies). These were removed from the packaging and rinsed with deionised 
water. The loading combs were then removed and gels transferred into the running 
apparatus, following which the running buffer (50ml 20X NuPageR was added to 950ml 
deionised water to prepare 1X SDS running buffer). The protein ladder (10µl) and protein 
samples (well volume 35µl) were then loaded using a pipette. For Cx43 20mcg of protein 
was loaded and for Cx43(Ser368) 60-80mcg of protein was loaded. Each protein sample 
was loaded in two wells. The gels were run at 200V for 1 hour or until all the protein 
marker band has run off the bottom of the gel. During this time TBS and TBST were 
prepared.  
 
On completion the gel cassettes were split open and the gel removed. This was then placed 
in the iBlot apparatus the iBlot stack was the added (the membrane had been soaked in 
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deionised water). On completion the blotting membrane and plastic tray were removed. 
The blot was washed with Ponceau S solution (to check for successful transfer of protein 
to the membrane) and then rinsed with deionised waster. 
 
The membrane was then placed in a 50ml universal container and blocked with 5% milk 
TBS for 60 minutes. A solution of the primary antibody [Cx43 (1:2000), Ser368 
(1:500) and GAPDH (1:4000)] was made up to 5ml using 5% Milk TBS. The 
membrane was allowed to incubate overnight at 4°C.  
 
The following day the primary antibody (was removed and stored - 0.02% of Azide [3.75 
µL of 20% Azide in 5 mL] was added for the purpose of to preservation. And the antibody 
stored in the fridge. 
 
The membrane was then washed at 10-minute intervals with TBS-T for 45 minutes, before 
being blocked again with 5% Milk TBS for 30 minutes. At this point 5 ml Secondary 
antibody (Goat anti-mouse- BioRad, Goat anti-Rabbit- BioRad attached to Horse Radish 
Peroxidase 1:2000 dilution. In 5% milk TBS (10 µL in 20 mL) to the membrane, which 
then allowed to incubate for 60 minutes at room temperature. The membrane was then 
washed at 20-minute intervals with TBS-T for 1 hour. The membrane was then washed with 
PBS (Sigma) for 10-minutes, prior to the addition of the ECL reagents (1.5 ml reagent A plus 
1.5 ml reagent A) and the membrane allowed to incubate for 1 minute.    
 
At this point blots were wrapped in cling film and analysed using Odyssey Imager 
acquisition system (LI-COR) using chemiluminescence and fluorescence. A digital 
representation of protein expression was generated, which allowed for data analysis.  
 
The blot was then re-probed for the protein standard to assess protein loading (in this case 
GAPDH). 
 
Following analysis the blots were re-wrapped in cling film and stored in PBS at 4oC, such 
that they could be re-probed if necessary. 
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5.2.8 Statistical Analysis 
 
Semi-quantitative analysis was performed. The mean signal identified from paired protein 
samples for Cx43 and Cx43(Ser368), was normalized and expressed graphically using Excel 
with standard error bars. 
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5.3 Results 
 
There were 23 patients recruited for skin biopsy with a view to culture of both keratinocytes 
and fibroblasts. Cell lines could only be cultured from 8 patients  (in 5 cases fibroblasts were 
cultured and in 3 cases keratinocytes were cultured). Fibroblasts proved slightly easier to 
culture and maintain.  
The demographic data of these patients is summarised in Table 5.2.  
 
Table 5.2 Summary of patient demographic data  
 
 
 
Control Group 
(n=3) 
PAOD (with DM) 
(n=2) 
PAOD (without DM) 
(n=3) 
Presentation 
Arterial Rest Pain 
Ulceration/Tissue Loss 
Mechanical Deformity 
 
0 
0 
3 
 
1 
1 
0 
 
2 
1 
0 
Mean age (range) 43 years (27-54 years) 74 years (64-83 years) 70 years (66-72 years) 
Sex (male) 1 2 1 
Mean Ankle/Toe Pressure 120mmHg/82mmHg 65mmHg/52mmHg 48mmHg/43mmHg 
Foot sepsis 0 0 0 
Pattern of Arterial Disease 
Aorto-iliac 
Femoral bifurcation 
Femoro-popliteal 
Femoro-popliteal/Crural 
Crural 
 
N/A 
N/A 
N/A 
N/A 
N/A 
 
0 
0 
0 
1 
1 
 
0 
0 
0 
2 
1 
Procedure 
Major Limb Amputation 
Infra-inguinal Bypass 
Complex Forefoot 
Reconstruction 
 
0 
0 
3 
 
2 
0 
0 
 
1 
2 
0 
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5.3.1 Protein extraction 
 
The quantity of protein extracted per well was poor. Given the relatively low protein yield 
some consideration was given to making the gels to run the Western-blot analysis as these 
could be created with larger wells, which would accommodate a greater volume. However 
this process was to prove time consuming and the quality of the blots (methodology of gel 
construct not described and data not shown) was not as good as the commercially available 
gels. This issue was overcome by pooling the protein harvested from 3-wells, which 
provided a low, but usable quantity of protein to allow the Western blot analysis to be 
performed.   
 
Figure 5.1 and Table 5.3 demonstrate the process (and result of) a Bradford protein assay 
with protein calculation. 
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Figure 5.1, Table 5.3 and Table 5.4 Bradford protein assay from human 
keratinocytes subjected to hypoxic challenge 
 
Table 5.3 Standard protein absorbance data 
 
Volume BSA 
(mg/ml) 
Absorbance at 595nm 
0 0.0169 
0.25 0.044 
0.5 0.092 
0.75 0.161 
1 0.191 
 
Figure 5.1 Linear regression model (Bradford protein assay) 
 
 
 
Table 5.4 Derived protein concentrations 
 
 Control (0 hour) 6 hour 12 hour 24 hour 
Absorbance at 595nm 0.586 0.748 0.906 0.719 
Protein in sample (mg/ml) 2.9 3.7 4.5 3.6 
Volume required (µ/l) for 
• 20mcg Protein 
• 80mcg Protein 
 
6.8 
27.2 
 
5.3 
21.3 
 
4.4 
17.6 
 
5.5 
22.2 
 
	 	 	 	
	 	 	 	 	 
 
y = 0.1996x - 0.0022 
R² = 0.98915 
-0.05 
0 
0.05 
0.1 
0.15 
0.2 
0.25 
0 0.2 0.4 0.6 0.8 1 1.2 
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5.3.2 Expression of Cx43 and Cx43(Ser368) from human fibroblasts and 
keratinocytes following hypoxic challenge 
 
As described fibroblasts were cultured from 5 patients (PAOD/DM n=1, PAOD 
n=2 and control n=2) and protein extracted for analysis (Cx43 n=3 and 
Cx43(Ser368) n=3). Fibroblast data following hypoxic challenge is summarised 
in Figures 5.2, 5.3 and 5.4. 
 
Figure 5.2 Western blot analyses for Cx43 and Cx43(Ser368) - Control 
A and B: Cx43 expression in fibroblasts with GAPDH control following hypoxic 
challenge  
C and D: Cx43(Ser368) expression in fibroblasts with GAPDH control following 
hypoxic challenge 
E and F: Data expressed as a mean for each time point for Cx43 and 
Cx43(Ser368) 
 
(A) Cx43 expression                           (B) GAPDH expression of blot A 
  
(C) Cx43(Ser368) expression              (D) GAPDH expression of blot C 
	  
(E) Cx43 expression                               (F) Cx43(Ser368) expression 
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Figure 5.3 Western blot analyses for Cx43 and Cx43(Ser368) – PAOD/DM  
A and B: Cx43 and Cx43 expression in fibroblasts following hypoxic challenge  
C and D: Data expressed as a mean for each time point for Cx43 and 
Cx43(Ser368) 
 
(A) Cx43 expression                                   (B) Cx43(Ser368) expression                        
  
(C) Cx43 expression                                    (D) Cx43(Ser368) expression 
  
 
Figure 5.4 Western blot analyses for Cx43 and Cx43(Ser368) – PAOD  
A and B: Cx43 and Cx43 expression in fibroblasts following hypoxic challenge  
C and D: Data expressed as a mean for each time point for Cx43 and 
Cx43(Ser368) 
 
(A) Cx43 expression                                   (B) Cx43(Ser368) expression 
  
(C) Cx43 expression                                    (D) Cx43(Ser368) expression 
	  
 
In these experiments there appeared to be consistent up-regulation of both Cx43 and 
Cx43(Ser368) at 12 and 24 hours irrespective of the cellular phenotype. 
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Keratinocytes were cultured from 3-patients (PAOD/DM n=1, PAOD n=1 and control 
n=1) and protein extracted for Cx43 and Cx43(Ser368) analysis. In keratinocytes the trend 
was for induction of Cx43 between 6 and 12-hours, with a similar pattern of induction 
demonstrated for Cx43(Ser368). The DM and non-DM keratinocytes did not seem to 
behave differently in terms of Cx43 and Cx43(Ser368) expression. These data are 
summarised in Figure 5.5, 5.6 and 5.7. 
 
Figure 5.5 Western blot analyses for Cx43 and Cx43(Ser368) - Control 
A and B: Cx43 expression in keratinocytes following hypoxic challenge  
C and D: Data expressed as a mean for each time point for Cx43 and 
Cx43(Ser368) 
 
 (A) Cx43 expression (Control)                        (B) Cx43(Ser368) expression (Control) 
	 	
(C) Cx43 expression                                        (D) Cx43(Ser368) expression 
	 	
 
 
 
 
 
 
 
 
 
 
 
 
 
0 
0.01 
0.02 
0.03 
Control 6 hours 12 hours 24 hours -0.02 
0 
0.02 
0.04 
Control  6 hours 12 hours 24 hours 
 
 
 85 
Figure 5.6 Western blot analysis for Cx43 and Cx43(Ser368) – PAOD/DM  
A and B: Cx43 and Cx43 expression in keratinocytes following hypoxic 
challenge  
C and D: Data expressed as a mean for each time point for Cx43 and 
Cx43(Ser368) 
 
(A) Cx43 expression                                       (B) Cx43Ser368) expression  
  
(C) Cx43 expression                                        (D) Cx43(Ser368) expression 
 
 
Figure 5.7 Western blot analyses for Cx43 and Cx43(Ser368) – PAOD 
(GAPDH control not shown) 
A and B: Cx43 and Cx43 expression in keratinocytes following hypoxic 
challenge  
C and D: Data expressed as a mean for each time point for Cx43 and 
Cx43(Ser368) 
 
(A) Cx43 expression                                        (B) Cx43(Ser368) expression 
  
 (C) Cx43 expression                                       (D) Cx43(Ser368) expression 
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5.3.3 The influence of high and low glucose environments on the expression 
of Cx43 and Cx43(Ser368) – Failed experiment 
 
This experiment was attempted with fibroblasts and keratinocytes using the 
protocol described above, which had been validated by other scientists within the 
laboratory.  
 
When the cells were 80% confluent in 6-well plates treatment with the high and 
low glucose solutions was started. There was no evidence of further cell 
proliferation during the 5-days of treatment and in some cases cell death was 
witnessed.  
 
The amount of protein that was extracted from the cells was so low (results of 
Bradford protein assays not shown) that Western Blot analysis could not be 
performed. 
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5.3.4 Expression of Cx43 and Cx43(Ser368) from human fibroblasts 
following peptidoglycan challenge 
 
The expression of Cx43 and Cx43(Ser368) in human fibroblasts following 
exposure to PGN was explored using cells from three patients (fibroblasts from 
PAOD/DU n=1; fibroblasts from control n=2). 
 
Figure 5.8 Cx43 and Cx43(Ser368) expression in human fibroblasts following 
peptidoglycan challenge 
A and B: Cx43 expression in human fibroblasts with GAPDH control following 
PGN challenge  
C and D: Cx43(Ser368) expression in human fibroblasts with GAPDH control 
following PGN challenge 
E and F: Data expressed as a mean for each time point for Cx43 and 
Cx43(Ser368) 
 
(A) Cx43 expression                            (B) GAPDH expression of blot A 
  
(C) Cx43(Ser368) expression              (D) GAPDH expression of blot C 
  
(E) Cx43 expression                              
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(F) Cx43(Serine 368) expression 
 
 
These data suggest that Cx43 is induced at 6 and 24 hours following PGN 
challenge. There was no evidence of Cx43(Ser368) phosphorylation being 
induced.  
 
(There is no comparable data available for Cx43 and Cx43(Ser368) expression in 
human keratinocytes following PGN challenge, because of the difficulties 
encountered culturing and maintaining these cell lines from the tissue samples 
collected).  
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5.4 Chapter summary 
 
These data seem to imply that in-vitro the protein expression of Cx43 and Cx43(Ser368) 
derived from both human keratinocytes and fibroblasts are upregulated by a hypoxic 
challenge. PGN challenge seems to induce Cx43, but had no influence on the expression of 
Cx43(Ser368). It is not possible to comment on the effect of metabolic dysfunction.  
 
A number of practical difficulties were encountered. Cell culture proved to be challenging 
and in many cases neither fibroblasts nor keratinocytes could be cultured despite strict 
adherence to the pre-defined local protocol. Protocols developed by other scientific teams 
were scrutinized, but despite minors modification of the cell harvest protocol no clear 
solution to this problem was identified during the research. 
 
Difficulty with cell culture should have been anticipated as in approximately 50% major 
limb amputation was being performed in the context of critical limb ischaemia. 
Presumably the severe distal ischaemia had an impact on the subsequent behaviour of the 
keratinocytes and fibroblasts. It is unclear as to why it proved so difficult to culture cells 
from the proximal skin biopsy sites. Infection did not seem to be an issue. It seems likely 
that issues with the skin was compounded by a significant methodological error at some 
point in the process contributed to failed cell culture attempts. 
 
In cases where fibroblasts and keratinocytes were cultured, the time from skin biopsy to 
experiment (performed when the cell line was 80% confluent) was significant – the mean 
time recorded for this process was 28-days. The long time from cell harvest to experiment 
persisted throughout the duration of the study. 
 
Another potential issue has been with the choice of GAPDH as a ‘housekeeping protein’. 
The protein worked well and has implied consistent protein loading (in the PGN 
experiments), however there is mixed evidence about its usefulness, with some authors 
suggesting that GAPDH may have limitations as a reference protein [Ferguson 2005]. 
Specifically there is some evidence that hypoxia may influence GAPDH expression and   
although this evidence is primarily based upon RNA analyses [Zhong 1999, Bär 2009] the 
pattern of GAPDH expression highlighted in Figure 5.2 (blots B and D) suggest that this is 
also the case for protein expression. Attempts were made to re-probe the blots with α-
Tubulin/β-Actin without success. 
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It was unclear as to why the keratinocytes and fibroblasts behaved as they did in the high 
and low glucose media. Given the difficulty with primary cell culture and the limited 
availability of cells, these experiments could not be repeated. 
 
There are two potential conclusions that we can make from these data. Firstly it would 
appear that Cx43(Ser368) protein expression might have utility as a biomarker for 
ischaemia in patients with PAOD and DFU, with apparent up-regulation of the protein at 6 
and 12 hours. Secondly Cx43 protein expression appears to be up-regulated by PGN 
challenge and given that infection is a significant potential issue in patients with DFU this 
would appear not to have clinical utility. However these conclusions must be interpreted 
with caution given the potential confounding issue of using GAPDH as the protein 
standard. These in-vitro results require further validation. 
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Chapter 6 – Discussion and Conclusions 
 
6.1 Introduction 
 
DFU is a challenging condition that will be encountered more frequently as a consequence 
of the significant increase in prevalence of DM with an aging population. In order to 
improve patient outcomes, identification of the at risk patient population may allow the 
multidisciplinary team to target resource and intervention to appropriately selected groups. 
For this to be effective, clear and unambiguous communication between members of the 
multidisciplinary diabetic foot care team is essential.  
 
In patients with neuroischaemic DFU the clinician is frequently challenged as to the 
appropriateness or otherwise of arterial reconstruction (endovascular or surgical). This is 
inextricably linked to the challenges of patient assessment and uncertainty about the 
impact of intervention for this pattern of ulceration and PAOD. Ongoing clinical trials such 
as BASIL-2 (NIHR Health Technology Assessment grant; project number 12/35/45) a 
multi-centre randomized trial comparing the outcome of endovascular and surgical 
intervention for patients with infra-geniculate PAOD (with or without concurrent femoro-
popliteal segment PAOD) may help inform opinion with regard to procedure choice for an 
individual patient, but will not help with the patient selection.  
 
Consequently two questions remain – Firstly can we identify the patient population with 
DFU who will benefit from intervention and secondly will we modify the natural history of 
the disease process with intervention. Unless the first question is meaningfully answered, 
truly understanding the appropriateness and effectiveness of our interventions will remain 
uncertain.  
 
Identification of a biomarker of ischaemia in this patient group could offer potential benefit 
in terms of guiding clinical decision making.  
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6.2 The effectiveness of University of Texas classification to describe diabetic foot 
ulceration  
 
These present data indicate that the clinical features defined by the UoT classification on 
first presentation, allow identification of patients most at risk of the major adverse events 
associated with DFU. Increasing ulcer depth and the presence of ischaemia and/or 
infection are independently associated with a significant increase in the requirement for 
major limb amputation and arterial reconstruction. These findings are consistent with other 
data demonstrating strong links between clinical characteristics and the likely clinical 
course of an individual ulcer [Jeffcoate 1993, Lavery 1996, Mills 2014]. Deeper ulcers and 
more advanced stage are also associated with an increased requirement for secondary care 
admission with septic complications. Finally, we have demonstrated that the development 
of recurrent ulceration is associated with an increased risk of major adverse clinical events 
even in the group presenting with apparently benign primary ulceration. 
 
To be effective a scoring system must be easy to apply, reproducible, identify high-risk 
cases and facilitate communication between different members of the multidisciplinary 
healthcare team [Teasdale 1974]. Clinical examination, defined as the presence or absence 
of a pedal pulse would seem to reliably identify patients with significant large vessel 
occlusive atherosclerotic arterial disease. Even with the potential shortcomings of such a 
basic categorical test, the high-risk foot seems to be identified [Byoko 1997]. A 
standardised clinical classification of sepsis has been defined [Lavery 2007], but there are 
limited data available to validate how this is applied for the various DFU scoring systems, 
creating the potential for inter-observer variability. However, despite these apparent 
limitations only eleven limbs in this series were “upgraded” during the follow-up period. 
This implies that despite the relatively crude nature of the clinical assessment UoT may 
appropriately classify DFU. 
 
The strengths of UoT classification are simplicity and an entirely clinically based 
assessment. The fundamental components of UoT have been embedded into the ‘Wound, 
Ischaemia and Foot Infection’ (WIfI) classification system described by the Society for 
Vascular Surgery (Mills 2014). This scoring system can be utilised to assess patients with 
and without DM. In this scoring system the diagnosis of ischaemia is based upon 
haemodynamic/perfusion measurements, rather than clinical examination. Retrospective 
validation has confirmed that this scoring system has prognostic utility (Cull 2014). 
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Although the addition of a haemodynamic measure of perfusion may be beneficial (the 
data may be valuable, particularly for research and measuring outcomes) it increases the 
complexity of the assessment process. Rather than engaging the primary healthcare team 
this could delay referral to and discussion with tertiary care. Furthermore there is no 
current evidence that assessment using WIfI confers any additional benefit over UoT in 
terms of identification of the ‘at risk’ limb. 
 
Any clinician assessing a patient presenting with DFU needs to consider whether sepsis is 
present and, if so whether urgent intervention to control sepsis is required. Similarly the 
extent to which large vessel occlusive arterial disease may be contributing to the 
presentation must be considered. Classifying the ulcer by the UoT system leads the 
clinician through this assessment process and generates prognostic information for the 
ulcer, limb and patient.  
 
There remains debate about the impact of some interventions on the natural history of DFU 
and this merits further investigation [Jude 2001*]. Two fundamental issues complicate 
defining the effectiveness of intervention – the heterogeneous nature of the patient 
population with variation in clinical assessment and variation in outcome reporting 
following intervention. These issues limit meaningful meta-analysis. Minor amputation 
rates are often reported, but the relationship of this to the outcome of the limb is weak in 
both this and previously series [Prompers 2008]. Minor amputation may often be required 
to achieve adequate surgical control of sepsis and as such probably represents a difficult 
and misleading measure of the quality of care in patients with DFU [Jude 2001*]. A rate of 
major limb amputation of approximately 5% per year following presentation with DFU has 
been described [Jude 2001, Engelhardt 2008, Chan 2015]. This clinical end-point is an 
attractive metric given its binary nature (as is amputation-free survival), but there are 
adverse events other than limb loss or death, which have significance to patients and 
healthcare systems. The disease process continues in other measurable ways and potential 
metrics to assess the effectiveness of an in intervention could include the number and 
duration of subsequent septic episodes (requiring admission for conservative and/or 
operative management), time to healing (of ulcers/surgical wounds) and ulcer recurrence. 
More difficult to assess are measures of mobility and independence following intervention. 
All of these features directly influence quality of life for patients with DFU [Elgzyri 2013].  
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Relevant to surgeons in particular, but all members of the multidisciplinary healthcare 
team is a reminder that one year after ‘successful’ intervention with limb salvage, 25% of 
patients will have unhealed surgical wounds or index ulcers [Chung 2006, Söderström 
2008].  Similarly, when assessing the impact of any of the components of the 
multidisciplinary care package it is important to note that some ulcers will heal when 
treated conservatively (Elgzyri 2013).  To further confuse matters, many ulcers fail to heal 
despite a functioning graft and there are few data that describe the impact of limb salvage 
surgery or surgical management of sepsis on recurrent infection rates, mobility, time spent 
in hospital or death due to sepsis.  Given the nature of the disease process, even successful 
interventions are unlikely to confer permanent protection from all future major adverse 
clinical events, and perhaps a modification of the natural history of the disease is the best 
that can be hoped for and outcomes assessed accordingly [Chan 2015]. 
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6.3 Connexin 43 and Connexin 43 (Serine 368) expression and in-vivo and in-vitro 
 
The expression of Cx43 in the tissue sections was similar in both the control and study 
groups (including the proximal skin biopsies from patients having both lower limb bypass 
and major limb amputation) and is consistent with previously published data. Cx43 
expression from the feet of these was also comparable to the patterns of expression 
identified in the skin biopsies of the leg (although morphologically the skin of the foot 
differs from that of the leg – thick skin and thin skin respectively). This is consistent with 
previous findings [Richard 2000, Brandner 2004, Richards 2005]. 
 
The apparent up regulation of Cx43(Ser368) in the skin biopsies taken from the ischaemic 
feet was a novel finding. Previous work [Richards 2004] has described the presence of 
Cx43(Ser368) in the stratum spinosum of normal skin, although was not demonstrated in 
this study. Up regulation of Cx43(Ser368) has been described as a consequence of injury, 
but these changes were not seen for approximately 6 hours and did not peak until 24 hours 
[Richards 2004]. Although by definition skin biopsy results in controlled epithelial trauma, 
it would seem unlikely that this in isolation could have generated such significant changes 
in Cx43(Ser368) protein expression. The skin biopsies from this study were taken directly 
to the laboratory on ice for fixation. These changes were not identified in any of the skin 
samples from the legs of patients (with and without DM), nor was it demonstrated in any 
of the control samples. Consequently it would seem likely that the changes in protein 
expression here are a true reflection of Cx43(Ser368) expression in the foot at the time of 
skin biopsy.  
 
The in vivo expression of Cx43(Ser368) was independent of a diagnosis of DM, implying 
that the changes reflect the ischaemic environment rather than the metabolic changes 
associated with glycaemia. In vitro is difficult to ascertain whether the protein expression 
from the human fibroblasts and keratinocytes was truly representative of the DM or non-
DM state. The cells were cultured under standardised laboratory conditions and the mean 
time from cell harvest to experiment was significant. Whether these cells retained a ‘DM 
phenotype’ through this process is uncertain. At an organ level the concept of ‘glycaemic 
memory’, a term that describes the delayed effects of previous hyperglycaemia on diabetic 
complications in later life, irrespective of subsequent improvements in glycaemic control 
has been discussed [UKPDS 1998, DDCT 2005]. Whether this concept is reflected at an 
individual cellular level in the human fibroblasts and keratinocytes cultured for these 
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experiments is less certain. There is some evidence from wound healing models 
demonstrating differences in migration of human fibroblasts and keratinocytes (derived 
from foreskin and skin biopsies) from DM and non-DM donors, even if the cells were 
maintained in euglycaemic conditions if they were investigated at an early passage 
[Pollock 2011]. If the cells in this experiment have similar characteristics to those 
described by Pollock et al we can assume that a DM phenotype has been maintained. If 
this is the case, then metabolic effects at a cellular level would not appear to influence the 
protein expression of Cx43 and Cx43(Ser368).  
 
As has been described previously the development and recurrence of DFU is complex with 
multiple potential mechanisms affecting a foot at any given time. From the 
immunohistochemistry a pattern of Cx43(Ser368) expression has been demonstrated which 
seems to be associated with ischaemia. However infective processes are relevant and 
important in the development and progression of DFU. Consequently it was unclear 
whether the Cx43 and Cx43(ser368) expression was potentially being modified by an 
inflammatory environment. The influence of pro-inflammatory mediators on Cx 
expression and function has highly cell-specific effects. Cx43 protein expression is up-
regulated [Garg 2005] in response to PGN in some cell lineages and down-regulated in 
others [Esen 2007]. At a cellular level GJ and CxHc function are also modified by PGN 
challenge, independent of changes in protein expression [Robertson 2010]. There is no 
similar work exploring the effect of PGN on Cx43(Ser368) protein expression, GJ or CxHc 
channel function. 
 
The potential effects of a gram-positive inflammatory response on Cx43 and Cx43(Ser368) 
protein expression in human fibroblasts has been explored in vitro with PGN challenge, 
with up-regulation of Cx43 protein expression, but no change in Cx43(Ser368) protein 
expression. These data would support the assertion that the up regulation of Cx43(Ser368) 
protein expression is related to ischaemia. However the absence of similar data from 
human keratinocytes mean that definitive conclusion cannot be made.  Furthermore 
infected DFU can represent a complex microbiological wound environment [Pellizzer 
2001, Armstrong 2004] and gram-negative organisms may be relevant. The effects of 
lipopolysaccharides (LPS), which can be found on the outer membrane of gram-negative 
bacteria, have not been explored in the present work. Previous authors have demonstrated 
changes in Cx43 protein expression and phosphorylation in response to LPS challenge 
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[Liddington 2002, Liao 2010]. The effect of LPS on the expression of Cx43(Ser368) 
protein expression has not been explored. 
 
Up regulation of Cx43(Ser368) protein associated with an acute wound seems to occur 
within 6 hours [Richards 2004, Pollock 2011]. The down regulation of Cx43 protein 
expression and up regulation of Cx43(Serine368) protein expression in the cardiac 
myocyte occurs quickly [Solan 2009, Pollock 2011, Johansen 2011]. In these experiments 
significant changes in Cx43 and Cx43(Ser368) protein expression have been demonstrated 
in vitro. Both Cx43 and Cx43(Ser368) protein expression were up regulated at 12 to 24-
hours and 6 to 12-hours respectively with a reduction in protein expression thereafter. This 
would appear to be consistent with previously published data.  
 
If this in vitro work is compared to a clinical vascular surgical presentation, this may be 
considered to be consistent with acute ischaemia (and is consistent with 
ischaemia/reperfusion models described by previous authors [Johansen 2011]). However, 
by definition all of the patients recruited to this study had chronic limb ischaemia. It may 
be that with longer periods of exposure to a hypoxic environment that there is a second 
peak in expression of Cx43(Ser368) protein. This merits further consideration and future 
investigation. 
 
It is not clear whether skin expressing of Cx43(Ser368) protein is recoverable. In each of 
the cases where Cx43(Ser368) protein was demonstrated in vivo the limb was considered 
to be non-recoverable and major limb amputation was performed. Consequently the natural 
history (defined on clinical grounds) was for progressive tissue loss in these cases. From 
the present data it is unclear what the effect of revascularisation/re-oxygenation has on the 
expression of Cx43(Ser368) protein . Although there was ethical approval to perform skin 
biopsy on the study population if they re-presented for a digital amputation or foot 
debridement following successful arterial reconstruction this was not required for any of 
the recruited patients did. This could be explored in-vitro. 
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6.4 Unanswered questions and future investigation 
 
In the first instance it would be important to validate the results presented here to justify 
the assertion that Cx43(Ser368) protein expression is a novel biomarker for ischaemia in 
skin. This would be best investigated in a group of patients undergoing either minor or 
major limb amputation, with a control group of patients having elective orthopaedic foot 
surgery.  
 
In a future study, as well as assessing haemodynamic measures of perfusion the addition of 
transcutaneous oxygen pressure measurement may add useful information. If up regulation 
Cx43(Ser368) protein expression as a consequence of ischaemia in skin were validated 
defining the clinical utility/relevance would have to be assessed. Conceptually it may be 
informative in the context of a patient with digital ulceration requiring minor amputation 
(for extensive ulceration/sepsis). At the time of the procedure a skin biopsy from the 
healthy wound margin could be examined and if Cx43(Ser368) is demonstrated this may 
help inform decision-making with regard to arterial reconstruction if an option is available.  
 
Whether skin biopsy could be justified from an ulcer margin (or elsewhere on a foot) that 
would not otherwise be managed surgically is not clear. There would have to be strong 
evidence from future study to justify this, given that there are a series of non-invasive 
investigations that can guide clinical decision-making. 
 
Cx43(Ser368) protein expression could have a useful role as a research tool. For example 
the angiosome concept has been widely discussed with limited data (a relatively small 
number of single-centre retrospective studies) available to justify conclusion. If 
Cx43(Ser368) can be demonstrated to vary either qualitatively or quantitatively, a trial 
could be conducted recruiting patients admitted for major limb amputation with biopsies 
taken from each of the six-angiosome territories. The results could then be correlated with 
the pattern of PAOD that had been defined by the pre-operative cross-sectional arterial 
imaging. 
 
There are also unanswered questions at a cellular level. Although conceptually this study 
did not seek to address these issues they are interesting and merit consideration and future 
investigation. Defining whether metabolic changes (hyperglycaemia/hypoglycaemia) 
influence the expression of Cx43(Ser368) protein is important if this protein is to be used 
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as a marker of ischaemia. Similarly identifying how Cx43 and Cx43(Ser368) protein 
expression are modified in response to re-oxygenation (in clinical terms re-perfusion 
following vascular surgical intervention) merits investigation. Finally defining how LPS 
influences Cx43(Ser368) protein expression is important if we are to define the specificity 
of this as a biological marker of ischaemia in skin. 
 
Identifying the changes in GJ and CxHc expression, structure and functionality in 
ischaemic skin and the physiological/pathophysiological significance of these with regard 
to Cx43 and Cx43(Ser368) protein expression is essential if we are to better understand the 
effect and implications of these changes at a cellular level.  
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6.5 Conclusion 
 
The complex pathophysiological processes that influence DFU make assessment 
challenging. Defining whether there is a significant ischaemic component as a 
consequence of PAOD relies on a constellation of clinical assessment, non-invasive 
investigation and radiological imaging. In isolation none of these can define the 
significance of PAOD and in this context a biological marker is an attractive concept. 
 
Cx43 protein expression in skin sections appears to be consistent and the protein was not 
distributed differently in patients with significant ischaemia. Cx43 protein expression 
appears to be up regulated by hypoxia in vitro, but is also influenced by PGN challenge. 
As such these data suggest that Cx43 protein expression does not have utility as a 
biological marker of ischaemia in patients with PAOD.. 
 
Cx43(Ser368) protein expression appears to be up regulated in response to hypoxia in skin 
and consequently may have a role as a biological marker ischaemia. As with pre-existing 
investigative strategies it seems likely that this would be incorporated into a multi-modal 
investigative approach, rather than being a stand-alone investigation. 
 
Further investigation is clearly required before a definitive conclusion can be made.  
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Appendix 1 – Solutions 
 
Chemical reagents were obtained from Sigma Life Science or Fisher. Reagents for 
electrophoresis were obtained from Biorad. 
 
Phosphate Buffered Saline (PBS) (Sigma Life Science)  
One tablet dissolved in 200ml of distilled water (sterilised by autoclaving for 121oC for 15 
minutes)  
 
Protein Lysis Buffer 
Prepared in RNase free eppendorf  
1% sodium dodecyl Sulphate [SDS]; 1mM dithioreitol and 3nM sodium orthoranadate; in 
870µl of PBS for a final volume of 1ml 
Prior to use 10µl phenylmethylsulphenyl [PMSF] (100nM) and 10µl of protease inhibitor 
cocktail [PIC] were added 
 
Tris-Buffered Saline and Tween 20 (TBS-T) 
50 mM Tris 
150 mM NaCl 
0.1% Tween 20 
Adjust pH with HCl to pH 7.4 - 7.6 
 
SDS Running Buffer (10x Stock) 
30g Tris  
144g Glycine 
10% SDS 100ml  (made up to 1000ml with distilled water) 
 
Protein Loading Buffer 
1ml β-Mecaptoethanol  
10% SDS  
400µl Stacking buffer  
2.5ml Glycerol  
4ml Distilled water 2.1ml and Bromophenol Blue 0.1%) 
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Appendix 2 – Presentations and Published Abstracts 
 
Hussey K, Kennon B and Stuart WP. University of Texas diabetic ulcer classification 
the limbs at risk from presentation to a diabetic foot clinic. British Journal of Surgery 
2015; 102 (S2): 1-3 
 
(Presented at the Vascular Society of Great Britain and Ireland ASM 2014 – British 
Journal of Surgery Prize Session) 
 
Introduction 
University of Texas (UoT) scoring is widely used to classify diabetic foot ulcers (a number 
indicates the ulcer depth and a letter describes the presence of sepsis and ischaemia).  It has 
been validated as a predictor of outcome for ulcer episodes.   
Methods 
We examined our database to establish utility of this tool to predict the outcome for a limb 
(ulcer duration, major amputations and salvage procedures).  The data were analysed by 
limb. 
Results 
Between 2005 and 2013 there were 971 ulcer episodes affecting 515 limbs (388 patients).  
UoT score implied peripheral arterial occlusive disease (PAOD) in 44.6% (UoT clinical 
groups C&D).  Median duration of ulceration per limb was 4 months (range 1-63), 
significantly higher in the PAOD cohort compared with the non-arterial groups (A&B).  
There was also a significantly higher risk of major amputation (13.5 v’s 4%) and.  21% of 
the PAOD limbs underwent salvage procedures (of which 31% still had a subsequent 
amputation), significantly more than in non-PAOD group (2%).  In only12 limbs was the 
PAOD status upgraded from presentation. 
Conclusions 
UoT scoring robustly identifies the highest risk foot ulcers, indicating patients requiring 
intervention and those at highest risk of amputation.  This may be a valuable tool for 
communication within the healthcare team. 
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Hussey K1, Wright C2, Martin P2 and Stuart WP1. Connexin 43 (Ser368) as a marker for 
ischaemia in diabetic foot ulceration. BJS 2016; 103 (S5): 5–30 
 
(Presented at the Vascular Society of Great Britain and Ireland ASM 2015 – British 
Journal of Surgery Prize Session) 
 
1. Department of Vascular Surgery, Southern General University Hospital, Glasgow 
2. Diabetes Research Group, Institute for Applied Health Research, Glasgow Caledonian 
University, Glasgow, G4 0BA 
 
Introduction 
The development and recurrence of diabetic foot ulceration (DFU) is multi-factorial. 
Identification of an ischaemic component can be difficult, given the indolent nature of 
neuroischaemic ulceration compounded by the presence of arterio-venous shunting and the 
frequently encountered distal pattern of arterial disease. We explored cutaneous expression 
of Connexin 43 (Ser368) in-vivo and in organotypic models of human skin.  
Methods 
Skin biopsies were performed on patients with and without diabetes undergoing arterial 
reconstruction or major limb amputation for critical limb ischaemia. 
Immunohistochemistry was performed using a primary Connexin 43 (Ser368) antibody. In-
vitro assessment using human fibroblasts and keratinocytes cultured from skin was 
performed after subjecting the cells to hypoxic conditions. Protein expression was 
evaluated using Western blot analysis. 
Results 
Immunohistochemistry provided qualitative data demonstrating expression of Connexin 43 
(Ser368) in skin biopsies harvested from ischaemic feet in all cases. Connexin 43 (Ser368) 
was not identified in any of the control specimens or in proximal skin biopsies of patients 
with occlusive arterial disease. When subjected to hypoxic laboratory conditions (5% 
oxygen) human fibroblasts and keratinocytes (from controls and study subjects) expressed 
Connexin 43 (Ser368) with protein expression peaking between 6 and 24 hours. These 
changes were not influenced by different glycaemic conditions. 
Discussion  
Cutaneous expression of Connexin 43 (Ser368) is a novel finding. These in-vivo findings, 
supported by organotypic modeling, suggest that Connexin 43 (Ser368) has potential 
utility as a biomarker for ischaemia in DFU. 
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Faniku C, Hussey K and Martin PE. The impact of diabetes and ischemia on Connexin 
and Pannexin expression in the skin. J Invest Derm 2016; 136(9): S257 
 
A major problem of diabetic foot ulcers is ischemia contributing to delayed wound closure. 
The gap junction protein Connexin43 (Cx43) is differentially remodelled during ‘normal’ 
and ‘chronic’ wound healing events. The mechanisms by which this protein is involved 
remains unresolved. This work investigated the expression and post translational 
modification of Cx43 and Pannexin 1 (Panx1) in skin biopsies from patients undergoing 
arterial reconstruction or major limb amputation for critical limb ischaemia and in 
keratinocytes cultured in normoxic (N) and hypoxic (H) (1% oxygen, 5% carbon dioxide 
and 94 % nitrogen) conditions. Skin tissue biopsies (proximal and distal to the point of 
venous bypass surgery) from diabetic and non-diabetic patients were processed for 
immunohistochemistry and stained with antibodies specific to Cx43 and Cx43Ser368. To 
model the events in vitro HaCaT cells were grown in 12 well plates, scrape wounded and 
cultured in N or H environments for up to 48 hours (h). Cell movement into the denuded 
area was recorded. Cells were fixed or protein harvested and expression of hypoxic 
inducible factor 1-a (HIF-1a), Cx43, Cx43Ser368, Panx1 and Ki67 determined by 
immunocytochemistry and Western blot analysis. Cx43 and Cx43Ser368 expression was 
significantly increased in the epidermis of skin biopsies isolated from the distal position 
(i.e. locations of ischaemia) in both diabetic and non-diabetic tissue. Scratch wound assay 
determined delayed wound closure in hypoxic conditions, that was confirmed by induction 
of HIF-1a expression. Cx43 and Cx43Ser368 staining showed translocation of the protein to 
the nucleus. No changes in Panx1 were observed. In conclusion, post translational 
phosphorylation of Cx43 occurs in chronically wounded diabetic and ischemic skin. Under 
H conditions, scrape wound closure is reduced and immunofluorescence suggests that 
Cx43 and Cx43Ser368 translocate to the nucleus after 24 h hypoxia. Thus, hypoxia impacts 
on Cx expression but not Panx1 expression in the epidermis. 
 
